AsthmaFINALGuideline10 14 2010

Evidence-Based Care Guideline for Management of Acute Exacerbation of Asthma in children aged 0 to 18 years
Health Policy & Clinical Effectiveness Program
Introduction
Evidence-Based Care Guideline
Management of
acute exacerbation of
ASTHMA
in children
Revision Publication Date: September 16, 2010
Revision Publication Date: September 3, 2002
Original Publication Date: July 20, 1998
Please cite as:
Acute Asthma Guideline, Cincinnati Children's Hospital
Medical Center: Evidence-based care guideline for management of
acute asthma exacerbation in children Asthma Exacerbation in
Children Pediatric Evidence Based Care Guidelines, Cincinnati
Children's Hospital Medical Center, Guideline 4, pages 1-35,
September 16, 2010
Target Population
Inclusion:
Children experiencing an acute asthma exacerbation:
up to 18 years of age with diagnosed asthma or high
probability of asthma presentation
0 to 12 months: accurate diagnosis of asthma in
this age range is difficult (see Attachment 1 Key
Indicators and Attachment 2 Differential
Diagnosis)
Exclusion: Children:
admitted to the intensive care unit (ICU)
who require intubation, ventilator support or are in
impending respiratory arrest
with bronchiolitis or conditions characterized by nonbronchodilator-responsive wheezing
Exercise caution in managing children with comorbid
conditions such as:
congenital or acquired cardiovascular disease
cystic fibrosis
chronic lung disease or bronchopulmonary dysplasia
immunodeficiency syndromes
Target Users
Include, but are not limited to:
Patient care staff, nurses, pharmacists, respiratory
therapists
Physicians, residents
Primary care providers, physician assistants
Guideline 4
9B
References in parentheses ( ), Evidence strengths in [ ] (See last page for definitions)

10B
Asthma is a disease of the respiratory tract

characterized by recurrent and/or chronic episodes of
airway inflammation and obstruction (manifested by
wheeze or cough, or demonstrated upon pulmonary
function testing) and evidence of reversibility of
obstruction.
Despite advances in the understanding of asthma and
development of effective medical interventions to
prevent morbidity and improve quality of life, asthma
remains a burden in prevalence, health care use and
mortality. There are significant ethnic and racial
disparities in asthma outcomes (Lai 2009 [4a], Ginde 2008
[4a], Jones 2008 [4a], Ferris 2006 [4a], Gupta 2006 [4a],
McDaniel 2006 [4a], Wilson 2005 [4a]) (see Section:
Disparities in Quality Care).
Prevalence in children continues to show an increasing

trend with reported rates between 8.5% and 8.9%
(Akinbami 2009 [4a], Kamble 2009 [4a], MMWR Moorman 2007

[4a]). Asthma is most prevalent in children 5 to 14 years
and in Puerto Rican and African-American children.

Among children younger than 18 years of age, asthma
is more prevalent in males (Akinbami 2009 [4a], MMWR
Moorman 2007 [4a]). The rate of asthma deaths among
children has declined from 1999 onward (Akinbami 2009
[4a], WorldHealthOrganizationWritingGroup 2006 [5a]).
Although this guideline is focused on the management

of the acute exacerbation in the emergency department
(ED) and inpatient settings (excluding the ICU), it is
recognized that asthma is a chronic inflammatory
disease and requires a safe transition of care to the
chronic care provider upon discharge.
The objectives of the guideline are to:
resolve the acute episode providing appropriate
therapies and decreasing the use of unnecessary
therapies
decrease risk of readmission to the ED or inpatient
unit
initiate or update chronic care management plan and
provide a discharge patient management plan
provide formal care transition to chronic care
provider
maintain and improve family satisfaction
Copyright 1998, 1999, 2002, 2010 Cincinnati Children's Hospital Medical Center; all rights reserved.
Page 1 of 36
Guideline Recommendations
Emergency Department Management

Initial History and Physical
1. It is recommended that before and as therapy is
initiated, a brief, focused history and physical
examination is obtained, including: (LocalConsensus [5],
NAEPP 2007 [5a])
time of onset of current exacerbation

current medications and allergies
recent frequent use of beta2-agonists
risk factors for severe, uncontrolled disease (e.g.
ED visits, admissions to the hospital and ICU,
and prior intubations)
exposure to asthma triggers
use of peak flow with home management
respiratory score.
Note 1: Indications of more severe exacerbation
include increased anxiety, decreased level of
consciousness, breathlessness, diffuse wheezing
or absence of air movement, increased
respiratory rate, and accessory muscle use or
suprasternal retractions (see Attachment 3
Formal Evaluation of Severity in the ED,
Attachment 4 ED Management of Asthma
Exacerbation Algorithm and Recommendation
#13 for severe asthma with respiratory distress).
Note 2: Perform a more detailed history and
physical assessment only after therapy has begun
(NAEPP 2007 [5a], Camargo 2009 [5b]).
Note 3: Patient and parental reports of
medication use, peak flow values and/or
environmental irritant/allergen exposure often
present a more favorable description of their
disease management than is actual (Dell 2007 [2a],
Kamps 2001 [2b], Bender 2000 [3b], Rich 2000 [3b],
Dozier 2006 [4a], Halterman 2003 [4a], NAEPP 2007
[5a]).
2. It is recommended that repeat assessments of

response to therapy be conducted, including clinical
examination, asthma score, pulse oximetry, and lung
function. In children with exacerbation, no single
assessment tool appears to be best for assessing
severity, treatment monitoring, or predicting
admission; therefore, use of one tool may not be
reliable (Sole 1999 [2a], Ribeiro de Andrade 2007 [3a], Keahey
2002 [3a], LocalConsensus [5], SIGN 2008 [5a], NAEPP 2007
[5a]).
3. It is recommended that forced expiratory volume in 1

second (FEV1) or peak flow monitoring be attempted
in children over 5 years with mild to moderate
Guideline 4
exacerbations and who currently perform peak flow

with home management (NAEPP 2007 [5a], Camargo 2009
[5b]).
Note: Pulmonary function measurements,
although often difficult to obtain in children, are
useful in assessing the severity of an asthma
exacerbation (Gorelick 2004 [3a]). If able to obtain,
and measurement is < 40% of predicted (or
personal best), consider adjunct therapies or
admission (NAEPP 2007 [5a]).
Initial Treatment
Oxygen
4. It is recommended that supplemental oxygen be
started and monitored when the oxygen saturation is
consistently less than 91% and to wean oxygen when
saturation is higher than 94% (Geelhoed 1994 [3a], SIGN
2008 [5a], NAEPP 2007 [5a]).
Short-acting inhaled beta2-agonists
5. It is recommended that racemic albuterol, an inhaled
short-acting beta2-agonist (SABA) be administered as
the drug of choice for rapid reversal of airflow
obstruction (NAEPP 2007 [5a], Camargo 2009 [5b]).
Modify therapy based on the early clinical response
to treatments (SIGN 2008 [5a], NAEPP 2007 [5a], Camargo
2009 [5b]) (see Table 1 Aerosolized Therapies drugs
and dosage recommendations).
Note: Albuterol treatments given every 10 to 20
minutes for a total of 3 doses can be given safely
as initial therapy (LocalConsensus [5], SIGN 2008 [5a],
NAEPP 2007 [5a]).
6. It is recommended that levalbuterol not be routinely
used in the treatment of acute exacerbation
(LocalConsensus [5]).
Confusion exists regarding the selection of albuterol
versus levalbuterol in the treatment of acute asthma.
Although levalbuterol may prove more efficacious
for some individuals, there is currently no data on
how to identify these patients (Jalba 2008 [1b]). The
following information may assist in the decision to
choose:
Note 1: Efficacy
Levalbuterol has demonstrated comparable
efficacy to albuterol for treatment of acute
exacerbations in the ED and inpatient settings
(Gupta 2007 [1b], Ralston 2005 [2a], Carl 2003 [2a],

Andrews 2009 [2b], Hardasmalani 2005 [2b], Qureshi 2005
[3a]). A large double-blind prospective trial
demonstrated a 10% reduction in hospital

admissions with the use of levalbuterol (Carl 2003
[2a]) and a retrospective review of consecutive
cases demonstrated a 4.5% reduction (Schreck 2005
Page 2 of 36
[4a]). The numbers needed to treat (NNT) with
levalbuterol to prevent one hospital admission in

theses studies equals 11 and 10 respectively (Carl
2003 [2a], Schreck 2005 [4a]).
Note: 2: Side effect reduction
Difference in the reduction of adverse events
such as tachycardia, tremor, or increase in blood
pressure has not been demonstrated when
equivalent doses of levalbuterol and albuterol
have been studied (Andrews 2009 [2b]).
The use of racemic albuterol with MDI has been
shown to result in lower pulse rates when
compared to nebulizer (Cates 2006 [1a], Mathew 2008
[1b ], Deerojanawong 2005 [2b], SIGN 2008 [5a]). This
may be an important consideration for children at
risk for tachycardia including children with
congenital heart disease or known arrhythmias
(LocalConsensus [5]).
Note 3: Cost
Given that there appears to be no safety
advantage to the use of levalbuterol, and the
ability to identify patients who have a differential
treatment response, the greatly increased cost of
the drug would argue against its use in the
general population. Discussion of the safety and
cost factors with parents may assist in the
selection process (LocalConsensus [5]).
Inhalation Delivery Device Selection
Devices used for the delivery of bronchodilators and
inhaled corticosteroids can be equally efficacious.
7. It is recommended that when selecting an inhalation
delivery device that consideration be given to the
following: (Dolovich 2005 [1a], Scarfone 2002 [3b])
device/drug availability
patient ability to use the selected device
correctly
device use with multiple medications
cost and reimbursement
drug administration time
convenience in both outpatient and inpatient
settings
physician and patient preference.
Note 1: In children and adolescents with acute
asthma exacerbation, no significant difference
exists for important clinical responses such as
time to recovery of asthma symptoms, repeat
visits, or hospital admissions when medications
are delivered via MDI with Valved Holding
Chamber (VHC) or nebulizer (Mathew 2008 [1b ],
Delgado 2003 [2a], Jamalvi 2006 [3a], Benito-Fernandez

2004 [3a], Yilmaz 2009 [4a]). Within this guideline, a
spacer is defined as a VHC or

delivery device
that has a one-way valve inside that prevents the
Guideline 4
medicine from escaping once you have pressed

down on the MDI canister (LocalConsensus [5]).
Spacers improve the clinical effect of inhaled
medications, especially in patients unable to use
an MDI properly (Lavorini 2009 [5b]). The use of
large volume spacers has been recommended for
any inhaled asthma drug in young children, and
as a means of reducing systemic bioavailability
of inhaled corticosteroids in adults and children
alike (Newman 2004 [5a]). One study has
demonstrated the percent difference of drug
deposition into the lung as 4.9% to 10.9% with
spacer use compared to no spacer. This
represents a range of approximately 52% to 87%
increase in drug deposition (Vidgren 1987 [4b]).
Note 2: MDIs have been shown to shorten time
to discharge from the ED, to improve pulmonary
function measures, and to result in lower pulse
rates when compared to nebulizer (Cates 2006 [1a],
Castro-Rodriguez 2004 [1a], Mathew 2008 [1b ],
Deerojanawong 2005 [2b], Boyd 2005 [3a],
LocalConsensus [5], SIGN 2008 [5a]).
Note 3: The inhalation route for SABA

administration is considered optimal.
Subcutaneous SABAs (epinephrine, terbutaline)
provide no proven advantage over inhaled
medication (NAEPP 2007 [5a]). Intravenous SABAs
have not been shown to improve pulmonary
physiology or outcomes compared to inhaled
routes (Travers 2001 [1a], NAEPP 2007 [5a]).
Inhaled ipratropium bromide
8. It is recommended that inhaled ipratropium be added
to SABA and corticosteroid therapies for children
presenting with moderate or severe acute
exacerbations or when the FEV1 is < 50% of
predicted (Plotnick 2009 [1a], Rodrigo 2005 [1a], Dotson 2009
[1b], LocalConsensus [5], SIGN 2008 [5a], NAEPP 2007 [5a],
Hayday 2002 [5a]) (see Table 1 Aerosolized Therapies -
drugs and dosage recommendations).

Note 1 : Adding multiple doses (up to 3 doses)
of anticholinergics to SABAs appears safe,
improves lung function and avoids hospital
admission in 1 of 12 school-aged children with
severe exacerbation (number needed to treat
[NNT] = 12) (Plotnick 2009 [1a]).
Note 2: Although ipratropium has been shown to
be efficacious in preventing hospitalizations for
children with exacerbations where FEV1 is <50%
of predicted, it has not been shown to provide
significant benefit after the child is hospitalized;
therefore, it is not a standard therapy to be
considered in the inpatient management of acute
exacerbations (Plotnick 2009 [1a], NAEPP 2007 [5a]).
Page 3 of 36
Guideline 4
Table 1: Aerosolized Therapies - Drugs and Dosage Recommendations

Aerosolized Therapies
Medication
Child Dose*
Adolescent Dose
(formulation)
Inhaled Short-Acting Beta2-Agonists (SABA)
Albuterol
Nebulizer solution
2.5 to 5 mg every 20 minutes for 2.5 to 5 mg every 20
(2.5 mg/3mL,
3 doses, then 2.5 to 5 mg every
minutes for 3 doses,
5 mg/mL)
1 to 4 hours as needed
then 2.5 to 10 mg
every 1 to 4 hours as
0.5 mg/kg/hour by continuous
needed,
nebulization
or 10 to 15 mg/hour
continuously
< 30 kg: 2.5 mg
MDI
(90 mcg/puff)
30 kg: 5 mg
6 puffs (range: 4 to 8 puffs)
every 20 minutes for 3 doses,
then every 1 to 4 hours as needed
6 puffs (range: 4 to 8 puffs)

every 20 minutes up to 4
hours, then every 1 to 4
hours as needed
Levalbuterol
0.075 mg/kg (minimum dose

1.25 to 2.5 mg every 20
Nebulizer solution 1.25 mg) every 20 minutes for 3
minutes for 3 doses, then
(0.31mg/3 mL,
doses, then 0.075 to 0.15 mg/kg
1.25 to 5 mg every 1 to 4
0.63 mg/3 mL,
(not to exceed 2.5 mg) every 1 to hours as needed
1.25 mg/0.5mL, 4 hours as needed
1.25 mg/3 mL)
MDI
See albuterol MDI dose above.
See albuterol MDI dose
(45 mcg/puff)
Above.
Anticholinergics in combination with Short-Acting Beta2-Agonist (SABA)
Ipratropium
bromide
Nebulizer
500 mcg with first 3 doses of
500 mcg with first 3 doses
solution
albuterol, (250 mcg may be used of albuterol, not to exceed
(500 mcg/2.5mL) where available)
1500 mcg in the first hour
not to exceed 1500 mcg in the
of treatment
first hour of treatment
MDI
4 to 8 puffs every 20 minutes as
8 puffs every 20 minutes as
(18 mcg/puff)
needed up to 3 hours
needed up to 3 hours
(R-albuterol)
Ipratropium
bromide with
albuterol
Nebulizer
solution
(Each 3 mL vial
contains 0.5 mg
ipratropium
bromide and 2.5
mg albuterol)
Notes
For optimal delivery, dilute aerosols to

minimum of 3 mL at gas flow of 6 to 8
L/min. Use large volume nebulizers for
continuous administration. May mix
with ipratropium nebulizer solution.
In mild to moderate exacerbations,

MDI plus VHC (see recommendation
7) is as effective as nebulized therapy
with appropriate administration
technique. Add mask in children
unable to manage an MDI device.
See Recommendation 6 of this
guideline regarding levalbuterol.
Not necessary as first line therapy in

children with mild exacerbations.
Add to SABA therapy for children
with moderate and severe
exacerbations.
Current formulation (HFA) is safe for
persons with peanut allergy.
May mix ipratropium bromide in same

nebulizer with albuterol.
1.5 mL every 20 minutes for 3
doses
3 mL every 20 minutes for

3 doses
Ipratropium is not necessary as first

line therapy in children with mild
exacerbations.
Add ipratropium to SABA therapy for
children with moderate and severe
exacerbations. Once the child is
hospitalized, further use of ipratropium
has not been shown to provide
significant benefit.
*Children < 12 years of age

Abbreviations: HFA = hydrofluoroalkane propellant; kg = kilogram; L/min = liter per minute; mcg = microgram; MDI = metered dose inhaler;
mg = milligram; mL = milliliter; SABA = short-acting beta2-agonist; VHC = valved holding chamber
Adapted from the National Heart Blood and Lung Institute, National Education and Prevention Program
Expert Panel Report 3: Diagnosis and Management of Asthma, 2007 (LocalConsensus [5], NAEPP 2007 [5a], Taketomo [5a]).
Page 4 of 36
Guideline 4
Table 2: Corticosteroids - Drugs and Dosage Recommendations

Medication
Prednisone
Prednisolone
Methylprednisolone
(sodium succinate)
Dexamethasone
Systemic Corticosteroids
Dosage
1 mg/kg once daily

(maximum 60 mg/day)
for a total of 5 days
Oral:
0.6 mg/kg once daily
(max 16 mg/dose)
for 1 to 2 days (Qureshi 2001 [2a])
Notes
Dosages in excess of 1mg/kg of prednisone or
prednisolone have been associated with adverse
behavioral effects in children, whereas 1mg/kg
provides equivalent pulmonary benefit with
decreased adverse effects (Kayani 2002 [2b]).
Intramuscular (dexamethasone sodium

phosphate):
0.6 mg/kg single dose
(max 15 mg) (Gordon 2007 [2a])
No advantage has been found for higher dose corticosteroids in severe asthma exacerbations.
There is no advantage for intravenous administration over oral therapy, provided gastrointestinal function is intact.
Therapy following a hospitalization or ED visit is typically 5 days, but may last from 3 to 10 days. Studies indicate there is
no need to taper the systemic corticosteroid dose when given up to 10 days.
Any previous IV doses may be considered as part of the total steroid dose.
Abbreviations: ED = emergency department; IV = intravenous; kg = kilogram; max = maximum; mg = milligram

Expert Panel Report 3: Diagnosis and Management of Asthma, 2007 (Chang 2008 [2a], LocalConsensus [5], SIGN 2008 [5a], NAEPP 2007 [5a],
Taketomo [5a]).
Corticosteroids
9. It is recommended that oral corticosteroids be
administered to patients who do not respond
completely to initial inhaled SABAs (Edmonds 2009
[1a], NAEPP 2007 [5a], Camargo 2009 [5b]) (see Table 2
drugs and dosage recommendations).
Note 1: Corticosteroids speed the resolution of
airflow obstruction, reduce the rate of relapse,
and may reduce hospitalizations, especially if
administered within one hour of presentation to
the ED (Rowe 2009a [1a], Edmonds 2009 [1a]).
Note 2: Oral prednisone has effects equivalent to
those of intravenous methylprednisolone
including tolerance by children (Rowe 2009a [1a],
SIGN 2008 [5a], NAEPP 2007 [5a], Camargo 2009 [5b]).
Note 3: For treatment of acute exacerbation,
insufficient evidence exists for inhaled
corticosteroid therapy alone or as an additive
benefit when used with systemic corticosteroids
(Edmonds 2009 [1a], Schuh 2006 [2b], Nakanishi 2003
[2b], NAEPP 2007 [5a], Camargo 2009 [5b]).
Note 4: If the patient is on routine inhaled

steroids for chronic control it is not necessary to
stop their use during exacerbation. The inhaled
corticosteroids can be started at anytime
regardless of oral dosing for the exacerbation
(LocalConsensus [5], SIGN 2008 [5a], NAEPP 2007 [5a]).
Note 5: It is recognized that many children will

have problems with treatment adherence due to
an oral aversion to medicine, especially bittertasting corticosteroid preparations. In such cases,

alternatives such as intramuscularly administered
dexamethasone, oral dexamethasone, and orally
administered intravenous versions of
corticosteroids have been proven efficacious
(Rowe 2009a [1a], Smith 2009 [1a], Gordon 2007 [2a],
Altamimi 2006 [2a], Qureshi 2001 [2a], Greenberg 2008
[2b], Huang 2007 [2b], Gries 2000 [2b]).
Adjunctive Therapies
Magnesium Sulfate
10. It is recommended in children with moderate to
severe exacerbations who are minimally responsive
or unresponsive to initial treatment (SABA, oral
corticosteroids, and ipratropium), that intravenous
magnesium sulfate be administered (Rowe 2009b [1a],
Mohammed 2007 [1a], Ciarallo 2000 [2b], SIGN 2008 [5a])
(see Table 3 Adjunctive Therapies - drugs and

dosage recommendations).
Note 1: In patients with acute exacerbation who
have been maximized on standard therapy,
intravenous magnesium sulfate has been shown
to reduce hospitalizations and to improve lung
function without significant side effects. Possible
side effects to be aware of include hypotension,
hypotonia, or abnormal reflexes when given
doses above that recommended for asthma (Rowe
2009b [1a], Mohammed 2007 [1a], Alter 2000 [1a]).
Page 5 of 36
Note 2: There is insufficient evidence regarding

the use of nebulized magnesium sulfate in acute
exacerbation (Blitz 2009 [1b]).
Epinephrine and Terbutaline
11. It is recommended for patients who are minimally
responsive or responding poorly to SABA /
ipratropium / systemic corticosteroid/magnesium
sulfate therapies, or who are unable to tolerate
aerosol treatments, that parenteral epinephrine or
terbutaline be considered (NAEPP 2007 [5a]) see Table
3 Adjunctive Therapies - drugs and dosage
recommendations).
Heliox
12. There is insufficient evidence and lack of consensus
regarding the effectiveness of heliox in acute
exacerbation of asthma to make a recommendation
for its routine use (Rivera 2006 [2b], SIGN 2008 [5a]).
Note: Heliox-driven albuterol nebulization may
be considered for patients who have lifethreatening exacerbation or who remain in severe
exacerbation after intensive conventional
adjunctive therapy (Rodrigo 2006 [1a], Kim 2005 [2b],
NAEPP 2007 [5a]). In one small study,
Guideline 4
improvement in respiratory score and shorter ED

length of stay were seen when heliox was
administered in moderate and severe
exacerbation (Kim 2005 [2b]).
Severe Asthma with Respiratory Distress and
Normal Mental Status
13. It is recommended that multiple therapies as
described below be started simultaneously while
either a consult from the Pediatric Intensive Care is
requested or transport to a higher level of care is
arranged (LocalConsensus [5]) (see Table 3 Adjunctive
Therapies- drugs and dosage recommendations)
Administer:
continuous albuterol
ipratropium bromide, up to 3 doses
systemic coticosteroids
(dexamethasone IM or
methylprednisolone IV)
epinephrine IM
magnesium Sulfate IV
consider terbutaline IV bolus, and infusion.
Table 3: Adjunctive Therapies - Drugs and Dosage Recommendations

Medication
Magnesium
Sulfate
Intravenous (IV)
Child (< 12 years of age)

Adolescent
Bolus: 50 mg/kg/dose (25 to 100 mg/kg/dose;
max 2 gms)
Administer over 20 minutes
Systemic (injected) Beta2-Agonists

0.01 mg/kg
Epinephrine
Intramuscular (IM)
(max 0.3 to 0.5 mg)
1:1,000
every 20 minutes
(1 mg/mL)
for 3 doses
Terbutaline
Intravenous (IV) or
Subcutaneous (SQ)
(1 mg/mL)
0.3 to 0.5 mg
every 20 minutes
for 3 doses
0.01 mg/kg bolus

(max 0.4 mg )
Over 10 minutes
0.01 mg/kg bolus

(max 0.75 mg)
Over 10 minutes
0.01 mg/kg
(max 0.25 mg)
May repeat every 15
minutes for 3 doses
0.01 mg/kg
(max 0.25 mg)
May repeat every 15
minutes for 3 doses
Notes
There is insufficient evidence regarding the benefit
from continuous infusion of Magnesium Sulfate
(Mohammed 2007 [1a]).
One small study demonstrated more rapid absorption

and higher plasma levels of epinephrine when
administered intramuscularly into the thigh compared
to subcutaneously or intramuscularly into the arm (up
to 4 times faster)(Simons 1998 [2b]).
Starting continuous infusion dose in the ED or PICU
settings: 1 mcg/kg/minute
Abbreviations: ED = emergency department; gms = grams; kg = kilogram; max = maximum; mcg = microgram; mg = milligram;
mL = milliliter; PICU = pediatric intensive care unit
Expert Panel Report 3: Diagnosis and Management of Asthma, 2007 (LocalConsensus [5], NAEPP 2007 [5a], Taketomo [5a]).
Page 6 of 36
Timing of Disposition from the Emergency

Department
The response to initial treatment in the ED after a period
of observation is a better predictor of the need for
hospitalization than is the severity of an exacerbation
(NAEPP 2007 [5a]).
14. It is recommended that the current severity of the
exacerbation be in the
mild range when evaluating
a child for discharge from ED or hospital
(LocalConsensus [5]) (see Attachment 3 Formal
Evaluation of Severity in the ED, Attachment 4 ED
Management of Asthma Exacerbation Algorithm) .
Note 1: In the ED, if initial severity is moderate
or severe, then the severity assessment 1 hour
after treatment is better than initial severity
assessment for determining the need for hospital
admission as well as for predicting the need for
ICU in patients initially assessed as severe (Kelly
2004 [3a], LocalConsensus [5]).
Note 2: In acute childhood asthma, a repeat pulse
oximetry of < 92 to 94 % at 1 hour after treatment
better predicts need for hospitalization than the
initial pulse oximetry (Kelly 2004 [3a], Wright 1997
[3b], LocalConsensus [5]).
Inpatient Management
General Therapy
15. It is recommended, with the exception of the use of
anticholinergics such as ipratropium, that usual
inpatient hospital management be viewed as a
continuation of any therapies initiated in the ED
including: (NAEPP 2007 [5a])
aerosolized bronchodilators
oxygen
corticosteroids
initiation and continuation of controller (antiinflammatory) agents
continued assessment
intermittent assessment of oxygen saturation
FEV1 or peak expiratory flow (PEF) on
admission, 15 to 20 minutes after bronchodilator
therapy during acute phase and daily until
discharge (in children > 5 years of age if able to
perform).
Failure to Progress
16. It is recommended that the following care be
initiated for patients who fail to progress after 12
hours of care: (LocalConsensus [5])
notify treating healthcare provider of any child
that has not progressed after 12 hours of care
assessment:
Guideline 4
physical examination and respiratory score

explore reason/s for failure to progress (e.g.
poor SABA responder, pneumonia or other
diagnosis, suboptimal steroid dose or
suboptimal frequency of administration)
escalate plan based on assessment findings
treatment considerations, as indicated:
albuterol treatments every 10 to 20 minutes
for 3 doses or continuous albuterol
administered over 30 minutes, and reassess
chest x-ray
administer or re-administer IV steroid if
greater than or equal to 12 hours since last
dose (oral or IM if cannot acquire IV
access)
venous or capillary blood gas
if status is improved after treatment escalation,
then reassess hourly
if status is not improved, discuss potential for
transfer to PICU or higher level of care
consider subspecialty consult.
Decompensation
17. It is recommended that the following care be
initiated for the patient whose condition is assessed
as decompensating from a prior stabilized state: (this
is not for the patient in an obvious medical
emergency for whom a medical code needs to be
initiated): (LocalConsensus [5])
albuterol treatments every 10 to 20 minutes for a
total of 3 doses or continuous albuterol over 30
minutes, and reassess
initiate the Medical Response Team (MRT) or the
team responsible for immediate assessment of a
child with a change in condition
notify treating healthcare provider that child is
decompensating
assess for treatment escalation options:
consider other adjunctive medications
- epinephrine IM
- ipratropium unless previously given
- magnesium sulfate unless previously given
administer or readminister steroid if indicated
(oral, IM, or IV if available)
insert IV
portable chest x-ray
prohibit eating or drinking (NPO)
consider capillary or venous blood gas
consider subspecialty consult
reassess after treatment escalation
if improved, resume hourly assessment
if not improved, transfer to PICU or higher
level of care.
Page 7 of 36
Consistency of Care
18. It is recommended that available protocols such as
clinical pathways or protocols be used, directing
consistent provision of care for patients presenting
with an acute asthma exacerbation (SIGN 2008 [5a],
NAEPP 2007 [5a]). At Cincinnati Childrens Hospital
Medical Center, such protocol usage includes:
Asthma Clinical Order set
Aerosol and Oxygen Protocol.
Note: Use of a clinical pathway or designated
care providers for inpatient management has
been shown to decrease length of stay, use of
SABA therapy, nursing and laboratory costs,
and to improve quality of care with no increase
in readmission rates (Johnson 2000 [2a], McDowell
1998 [2a], Norton 2007 [4a], Wazeka 2001 [4a],
Ebbinghaus 2003 [4b], Kelly 2000 [4b]).
Guideline 4
environmental, adherence, financial, psychosocial or

health literacy (LocalConsensus [5]). The CARAT may
be accessed via the following URL:
http://carat.asthmarisk.org
Consultations
22. It is recommended that the need for consultations be
considered at the time of presentation or as early as
possible in the acute course (LocalConsensus [5]).
Medical consultation: Usual indications for medical
consultation (usually, a fellowship-trained allergist or
pulmonologist; occasionally, other physicians who
have expertise in asthma management, developed
through additional training and experience) in
childhood asthma include: (LocalConsensus [5], NAEPP
2007 [5a])
Complementary and Alternative Medicine

19. It is recommended that the clinician ask
patients/parents about all medications and treatments
they are using for asthma (LocalConsensus [5], NAEPP
2007 [5a]).
Note 1: A high level of use of complementary
and alternative medicine (CAM) has been
reported in several studies: 45% of care providers
reported using herbal products with their children
(Lanski 2003 [3a]), 63% of adolescents reported the
use of complementary medicine when surveyed
(Reznik 2002 [3a]), and a review of literature of
CAM use in asthma found the level ranged from
33% to 89% in studies of children and adolescents
(Mark 2007 [1b]). Currently there is insufficient
evidence to support or refute the use of CAM
therapies (Altunc 2007 [1a], Hondras 2005 [1a], Mark
2007 [1b]).
Note 2: Patients who use herbal treatments may
need caution regarding the potential for harmful
ingredients in herbal treatments and interactions
with asthma medications (Lanski 2003 [3a], NAEPP
2007 [5a]).
the diagnosis of asthma is in question

current life-threatening or severe asthma
exacerbation possibly requiring MRT (medical
response team)
poor-responder or requiring escalation in routine
care or unexplained deterioration
repeated life-threatening hospital admissions,
history of intensive care admission, frequent ED
visits for asthma
patient has required more than two bursts of oral
corticosteroids in the past 12 months
any exacerbation requiring hospitalization in the
last 12 months
evaluation for addition or discontinuation of
LABA therapy
conditions complicating asthma or its diagnosis
(e.g. sinusitis, nasal polyps, aspergillosis, severe
rhinitis, vocal cord dysfunction, gastroesophageal
reflux, and chronic obstructive pulmonary
disease)
need for extensive education and guidance on
allergen avoidance, problems with adherence to
therapy and poor control, or complications of
therapy.
20. It is recommended that acupuncture not be used for

the treatment of asthma. No evidence of an effect of
acupuncture in reducing asthma symptoms has been
demonstrated (McCarney 2009 [1a], Martin 2002 [1a],
NAEPP 2007 [5a]).
Mental Health consultation: Patients who have

significant psychiatric, psychosocial, or family
problems that interfere with their asthma therapy may
need referral to an appropriate mental health
professional for counseling or treatment.
ED or Inpatient Management
Screening
21. It is recommended that systematic screening be
conducted using a broad assessment tool, such as
Child Asthma Risk Assessment Tool (CARAT) for
identification of risks including medical,
Social Service Consultation: Indications for

considering social service consultation include:
family's social or financial difficulties might be
impediments to adherence with the treatments and
medical follow-up
family resources are compromised or uncertain
Page 8 of 36
Interpreter Services Consultation: Indication for

considering services:
family in need of language interpretation
Pharmacist Consultation: Indications for
considering pharmacist consultation (where
available) include review of the medication regimen
of a patient admitted for asthma exacerbation
Note: Medication regimen evaluation may
include: screening for adverse drug reactions,
screening for drug interactions, ensuring
appropriate medication use and dosing,
appropriate route of administration, appropriate
dosing intervals and/or comparison of the
medication reconciliation record with the
current medication orders (Sanghera 2006 [1a],
Kaushal 2008 [3a]).
Therapies Generally NOT Recommended
23. It is recommended that theophylline or
aminophylline not be administered routinely in the
ED or hospitalized patient because they do not appear
to provide additional benefit to optimal SABA therapy
(D'Avila 2008 [2b]) and may increase frequency of
adverse effects in acute exacerbation (Mitra 2009 [1a],
SIGN 2008 [5a], NAEPP 2007 [5a]).
Note 3: Patients using theophylline as

outpatients may continue on their usual doses in
the hospital; obtaining a therapeutic level while
the child is hospitalized may be considered,
because illness can affect serum levels.
Additionally, a pharmacist consult may be
useful for review of drug interactions (NAEPP
2007 [5a]).
24. It is recommended that antibiotics not be used

routinely for acute asthma exacerbations in the
absence of an identified bacterial focus (Graham 2009
[1a], SIGN 2008 [5a], NAEPP 2007 [5a], Blasi 2007 [5b]) .
25. It is recommended that aggressive rehydration not
be used routinely for acute asthma exacerbation in
the absence of clinical dehydration (NAEPP 2007 [5a]).
26. It is recommended that chest physiotherapy (CPT),
incentive spirometry, and mucolytics not be used
routinely for acute asthma exacerbations as they can
trigger bronchospasm or worsen cough or air flow
obstruction during an acute asthma attack (NAEPP
2007 [5a]).
27. It is recommended that anxiolytic and hypnotic
drugs not be used routinely for acute asthma
exacerbations outside of an intensive care setting, as
they may cause respiratory depression (NAEPP 2007
[5a]).
Guideline 4
28. It is recommended that oral albuterol not be used

for acute exacerbation (LocalConsensus [5]).
Therapy Cautions/Considerations
29. It is recommended that for therapies outlined in this

section, caution and consideration be used in
treatment selections (LocalConsensus [5]).
Ibuprofen: In children without known Aspirin Induced
Asthma (AIA), ibuprofen may be a better choice than
acetaminophen for the treatment of fever/pain in children
presenting with acute asthma exacerbations.
Acetaminophen has been associated with an increased risk
of wheezing (Kanabar 2007 [1a], Karimi 2006 [4a]).
In children with known AIA, it is prudent to counsel
parents regarding the potential for cross-sensitivities to
non-steroidal anti-inflammatory drugs (NSAIDs) (Debley
2005 [1a]). This patient population demonstrates less crosssensitivity to acetaminophen.
Cross-Sensitivities: (Jenkins 2004 [1a])
ibuprofen < 400mg
98%
naproxen < 100mg
100%
diclofenac < 40mg
93%
acetaminophen > 500mg 7%
Long-Acting Beta2-Agonists
Epidemiological evidence suggests a link between longacting beta2-agonists (LABAs) and increases in asthma
mortality. Concern remains that symptomatic benefit
from treatment with LABAs might lead to
underestimation of acute attack severity and long-term
use could lead to tolerance to their bronchodilator
effects (Cates 2009b [1a], Cates 2009a [1a]). In addition,
recent analyses by the Food and Drug Administration
(FDA) and others concluded that use of LABAs is
associated with an increased risk of severe worsening of
asthma symptoms, leading to hospitalization in both
children and adults and death in some patients with
asthma (Salpeter 2010 [1a], Walters 2007 [1a], Salpeter 2006
[1a], FDA 2010 [5]). The FDA is requiring further studies
for safety evaluation and has concluded that although
these medicines play an important role in helping some
patients control asthma symptoms, their use be limited
to patients whose asthma cannot be controlled with
inhaled corticosteroids alone (FDA 2010 [5]). There is no
good evidence as to which subpopulation would benefit
or be harmed with use of a LABA. One recent study,
evaluating step-up therapy in children, concluded that
response to LABA was more likely to provide a better
response compared to ICS or leukotriene-receptor
antagonist (LTRA). However many children had a best
response to ICS or LTRA step-up, highlighting the need
to regularly monitor and appropriately adjust each
Page 9 of 36
childs asthma therapy within this level of care before

further step-up (Lemanske 2010 [2a]).
Until further studies are concluded, it is suggested
that all patients treated with LABA be individually
evaluated to ensure that this is the best option for
asthma control (Cates 2009b [1a], Cates 2009a [1a]).
Such evaluation may best be performed in
conjunction with an Asthma Specialist
(LocalConsensus [5]) (see Recommendation #35 for
evaluation of LABA use).
Disparities in quality of care: When treating children
with asthma, it is important to consider the
socioeconomic factors that might lead to avoidable
hospitalizations and premature mortality (Cope 2008 [4a],
Gupta 2006 [4a]). Special consideration of the following
conditions assists in the provision of patient-centered,
equitable care:
Medicaid-covered, minority children have worse
asthma status (parental report) and are less likely to
be using preventive, anti-inflammatory agents than
white children (Ferris 2006 [4a], Lieu 2002 [4a]).
Children uninsured or on Medicaid have ranked
significantly lower on seven quality measures
including ED utilization, prescriptions from the ED,
and access to and use of a primary care provider
(Lara 2003 [2a], Knudson 2009 [4a], Wilson 2005 [4a], Ferris
2001 [4a]).
Black children demonstrate more likelihood to have

asthma and to experience ED visits for asthma,
compared with otherwise comparable white children
(Flores 2005 [3a], Jones 2008 [4a]).
The effect of comorbid conditions and mental illness
in mothers of asthmatic children has recently been
shown to impact asthma control and health services
utilization related to asthma (Coughlan 2001 [1a],
Bartlett 2001 [3a], Belamarich 2000 [3a], Rodriguez 2002
[4a], Shalowitz 2001 [4a], NAEPP 2007 [5a]) (see
Recommendation #22, Consultations, Social

Services).
Discharge/Transition Preparation
Although this guideline is focused on the acute

management of asthma exacerbations, it is recognized
that asthma is a chronic disease. Discharge planning is
intended to assist the transition from the acute
exacerbation to chronic management, identifying factors
within the chronic action plan that may need adjusting to
prevent future exacerbations and improve long-term
patient outcomes. The transition plan is expected to
enhance the likelihood that the family, and ultimately
the child, will become skilled in self-management of this
chronic condition. Early planning is important to assure
Guideline 4
that problems with details associated with follow-up

have been resolved prior to discharge.
Recommendations for comprehensive management of
chronic asthma can be found in the most recent update
of the national asthma guideline (NAEPP 2007 [5a]).
30. It is recommended that planning for discharge begin
when the child first presents to the ED or hospital
unit (LocalConsensus [5]).
31. It is recommended that prior to discharge the patient
undergo Severity Classification of chronic asthma (see
Attachment 5 Severity Classification). This will
support a patient-centered approach to therapy (NAEPP
2007 [5a]). Also, Severity Classification may be useful
to the primary care provider in identifying children
with special health care needs and facilitating care
coordination (LocalConsensus [5]).
32. It is recommended that case or care management by
trained health professionals be considered for
patients who have poorly controlled asthma and have
recurrent visits to the ED or hospital. Caremanagement processes are tools to improve the
efficiency and quality of primary care delivery, self
management, and have demonstrated a reduction in
ED visits (Schulte 2004 [1b], Levy 2006 [2a], Walders 2006
[2a], Griffiths 2004 [2a], Portnoy 2006 [4a], Rosen 2006 [4a],
Spiegel 2006 [4a], Wood 2006 [4a], Allcock 2009 [4b], CMSA
2010 [5]).
33. It is recommended, before the patient is discharged

from the ED or inpatient unit, that education be
provided that is tailored to the identified needs,
beliefs, and learning styles of the patient and family
and addresses identified patient-desired outcomes
(Zorc 2005 [2a], LocalConsensus [5], Mansour 2009 [5a], SIGN

2008 [5a], NAEPP 2007 [5a]).
Note 1: When usual care for asthma was

compared to more intensive educational programs
(provided in either the ED, hospital, home or
clinic), reduction in subsequent ED visits and
hospital admissions occurred in those receiving
intensive education (Boyd 2009 [1a], Wolf 2008 [1a],
Karnick 2007 [2a], Brown 2006 [2a], Ng 2006 [2a],
Sockrider 2006 [2a]). The most effective type,
duration or intensity of education has not been

determined (Boyd 2009 [1a], Coffman 2008 [1a], Wolf
2008 [1a], Zorc 2009 [2a]). Patient-centered, specific
education efforts may be more effective than
general or poorly targeted interventions (Canino
2008 [2a], Forbis 2002 [2b], NAEPP 2007 [5a]).
Note 2: Asthma education plans have been

successfully implemented in busy EDs (Boychuk
2006 [3a], NAEPP 2007 [5a]).
Page 10 of 36
Components of education programs have not been

comparatively studied; however, programs that have
demonstrated improvement have included the following
components: (Boyd 2009 [1a], Coffman 2008 [1a], Wolf 2008 [1a])
etiology, prognosis, and risk factors emphasizing
chronicity of condition
medication purpose, and when and how to use
medications (Smith 2008 [4a])
provision or updating of written asthma plan
Note: Parental attitudes toward and knowledge of
asthma (pathophysiology, medications, action
plans, and environmental triggers) influenced
adherence to prescribed asthma medications and
action plans in several studies (Jones 2002 [2a],
Douglas 2002 [2b], NAEPP 2007 [5a]).
identification of environmental triggers for prevention
of acute exacerbations (Lanphear 2001b [4a], Lanphear
2001a [4a]) (see Attachment 6 How to Control what
Makes Your Asthma Worse)
Note: Multifaceted allergen education and control
interventions delivered in the home setting have
been shown to be effective in reducing exposures
to cockroach, rodent, and dust-mite allergens and
associated asthma morbidity (Arshad 2007 [2a],
Morgan 2004 [2a], Schonberger 2004 [2a], Chan-Yeung 2002

[2a], Custovic 2001 [2a], Finn 2000 [3a], NAEPP 2007 [5a]).
demonstration of correct use of inhaler / spacer (HussainRizvi 2009 [2b]) (see Attachment 7 MDI Use)
demonstration of peak flow technique if sending home

with peak flow meter (for patients with moderate or
severe persistent asthma or a history of severe
exacerbations, or patients who are poor perceivers of
airflow obstruction) (see Attachment 8 Peak Flow Use)
Note: Peak flow measurement can be a useful
addition for severity assessment of an asthma
exacerbation and is most useful in patients with
moderate to severe persistent asthma (McMullen 2002
[2a], Yoos 2002 [2a]). It can be used in short-term
monitoring, acute exacerbations, and daily chronic
monitoring (Goldberg 2001 [4a], Brand 1999 [4a], NAEPP
2007 [5a]).
home management of exacerbation or relapse

including evaluation of early clinical signs and
symptoms of airway inflammation
Note: Beginning treatment at home may avoid
treatment delays, prevent exacerbations from
becoming severe, and also adds to patients sense
of control over their asthma. The degree of care
provided in the home depends on the patients (or
parents) abilities and experience and on the
availability of emergency care (NAEPP 2007 [5a]).
Accurate evaluation of symptom severity by
parents and children will assist to avoid delays
Guideline 4
in care and inappropriate home management

(Garbutt 2009 [2a]).
importance and purpose of follow-up appointment
explore action plan, evaluate patient goal attainment,
identify barriers to meeting activity goals, identify
potential treatment adjustments to help meet goals and
prevent future exacerbations (Zorc 2005 [2a], Zorc 2003
[2a], Flores 2005 [3a]):
schedule before discharge for hospitalized
patient 1 to 5 days after discharge
contact primary care provider before discharge
from ED
importance of continual and consistent care in
outpatient setting, partnering with primary care
provider to tailor interventions toward the childs
goals for activity
provision of Asthma Specialists resource information
if indicated.
34. It is recommended that SABAs be used at home on an
as-needed basis after recovery from an acute asthma
exacerbation (Walters 2002 [1a], NAEPP 2007 [5a]). If
patients need is greater than 6 puffs every 3 to 4
hours by 24 to 48 hours after discharge provide family
with instruction to seek medical care (LocalConsensus
[5]).
35. It is recommended that if a LABA was in use before
admission, it be suspended during hospitalization for
exacerbation and the patient be evaluated for
continuation of therapy after discharge: (LocalConsensus
[5], SIGN 2008 [5a]).
Note 1: There is no evidence that continuing a
LABA during exacerbation is beneficial and
concern remains regarding harm with its
continued use.
Note 2: The beneficial effects of LABA in
combination therapy for the patients who require
more therapy than low-dose ICS alone to control
asthma need to be weighed against the potential
increased risk of severe exacerbations, associated
with the daily use of LABAs in some patients
(Cates 2009b [1a], Cates 2009a [1a], Nelson 2006 [2a],
NAEPP 2007 [5a]).
Consider consultation with an Asthma Specialist

for questions regarding continuation of LABA
following hospital discharge (LocalConsensus [5]).
Note 3: In February of 2010 the FDA announced
new safety controls for LABAs as follows:
LABAs are contraindicated without the use

of an asthma controller medication such as
inhaled corticosteroid, and should not be
used alone (FDA 2010 [5], NAEPP 2007 [5a]).
Page 11 of 36
LABAs ought to only be used long-term in

patients whose asthma cannot be adequately
controlled on other asthma controller
medications (FDA 2010 [5]).
LABAs ought to only be used for the

shortest duration of time required to achieve
control of asthma symptoms and
discontinued, if possible, once asthma
control is achieved (FDA 2010 [5]).
Note 4: Of the adjunctive therapies available,
LABAs are the preferred therapy to combine with
ICS in youths 12 years of age and adults (NAEPP
2007 [5a]).
Note 5: For patients 5 years of age who have
moderate persistent asthma or asthma
inadequately controlled on low-dose ICS, the
option to increase the ICS dose may be given
equal weight to the option of adding LABA
(NAEPP 2007 [5a]). A recent study suggests that
patients are most likely to have a differential
response to the addition of LABA to low dose
ICS compared to increasing ICS or adding a
leukotriene receptor antagonist. However, the
safety of long term use of LABA remains
uncertain (Lemanske 2010 [2a]).
Note 6: For patients 5 years of age who have
severe persistent asthma or asthma inadequately
controlled, the combination of LABA and ICS is
the preferred therapy (NAEPP 2007 [5a]).
Note 7: For patients < 4 years of age, there is
insufficient evidence for use of a LABA. These
drugs are not labeled for use in this age group.
Consider consultation with an Asthma Specialist
for questions regarding this subset of asthma
patients before adding LABA therapy
(LocalConsensus [5], NAEPP 2007 [5a]).
36. It is recommended that patients already on ICS
continue ICS therapy after discharge from ED or
inpatient setting. Consider initiating ICS for patients
with persistent asthma if not already receiving (SIGN
2008 [5a], NAEPP 2007 [5a]).
Note: Initiating ICS at discharge for patients not
already on ICS has demonstrated a decreased risk
of subsequent ED visits for patients with persistent
asthma (Sin 2002 [4a], NAEPP 2007 [5a]).
37. It is recommended, when possible, that long term
controller medications and medicines to complete
exacerbation therapy are provided to the patient prior
to discharge (Qureshi 2001 [2a], Cooper 2001 [4a]).
Note: Prescriptions are not always filled after
discharge (Qureshi 2001 [2a], Cooper 2001 [4a]).
Outcomes demonstrated from prescriptions not
Guideline 4
filled have been an increase in missed school and

work days (Qureshi 2001 [2a]). It is also believed
that providing medicines will result in decrease
readmission rates (LocalConsensus [5], NAEPP 2007
[5a]).
38. It is recommended that patients have a written plan
that reflects adjustments necessary due to the current
exacerbation and includes a stepwise approach
coordinating with the childs plan for chronic
management (Zemek 2008 [1a], Bhogal 2006 [1a], NAEPP
2007 [5a]) (see Attachment 9, Stepwise Management).
39. It is recommended that every attempt be made to
schedule the follow-up appointment before the
child is discharged from the facility. When this is
not possible, attempt to notify the primary care
provider of the current exacerbation event (Zorc 2005
[2a], Zorc 2003 [2a], LocalConsensus [5], NAEPP 2007
[5a]).
Note: A significant number of patients from the

Cincinnati population consider the ED their
regular source of care, and a commonly held
health belief is that the ED is the appropriate place
to seek care for a breathing problem (Mansour 2000
[2b]). Having fewer general practice contacts in
the previous year has been independently
associated with an increased risk of fatal asthma,
increasing the importance of the follow-up visit
either with the primary care provider or asthma
specialist (LocalConsensus [5], NAEPP 2007 [5a]).
Discharge readiness
Ongoing assessment will provide the needed information

of the patient progression to determine the readiness for
discharge. Discharge readiness usually includes the
following:
child stable on therapies that can be administered at
home
home environment is able to safely fulfill discharge
plan
sufficient knowledge of asthma to manage care at
home or seek help if symptoms worsen
arrangements for any special medications or
equipment required for home therapies are complete
transition plan based on admission screening is
complete and reflects the patients continuum of care
needs
follow-up care is arranged, coordinating with
primary care provider or asthma specialist if
indicated, and providers agree with plans.
Page 12 of 36
Guideline 4
Future Research Agenda

Clinical questions of potential interest to CCHMC
investigators related to the population of children 12
months to 18 years of age with acute asthma:
1. Does the discontinuation of LABA upon
exacerbation compared to continuation of LABA:
decrease the length of exacerbation?
decrease the number of treatment failures (e.g.
decompensation, admission)?
2. Does the use of same dose Levalbuterol compared
to Albuterol:
decrease admissions?
decrease costs?
decrease cardiac adverse events (e.g.
tachycardia, arrhythmia)?
3. Does the use of a respiratory score compared to no
score:
decrease length of stay?
CCHMC Guideline Implementation Tools

Any available implementation tools are available online
and may be distributed by any organization for the
global purpose of improving child health outcomes.
Website address:
http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/evbased/default.htm
Page 13 of 36
Guideline 4
Attachment 1
KEY INDICATORS FOR CONSIDERING A DIAGNOSIS OF ASTHMA
Consider a diagnosis of asthma and performing spirometry if any of these indicators is present.*
These indicators are not diagnostic by themselves, but the presence of multiple key indicators
increases the probability of a diagnosis of asthma. Spirometry is needed to establish a diagnosis of
asthma.
Wheezinghigh-pitched whistling sounds when breathing outespecially in children. (Lack
of wheezing and a normal chest examination do not exclude asthma.)
History of any of the following:
Cough, worse particularly at night
Recurrent wheeze
Recurrent difficulty in breathing
Recurrent chest tightness
Symptoms occur or worsen in the presence of:
Exercise
Viral infection
Animals with fur or hair
House-dust mites (in mattresses, pillows, upholstered furniture, carpets)
Mold
Smoke (tobacco, wood)
Pollen
Changes in weather
Strong emotional expression (laughing or crying hard)
Airborne chemicals or dusts
Menstrual cycles
Symptoms occur or worsen at night, awakening the patient.
*Eczema, hay fever or a family history of asthma or atopic diseases are often associated with asthma, but
they are not key indicators.
(NAEPP 2007 [5a])
Page 14 of 36
Guideline 4
Attachment 2
DIFFERENTIAL DIAGNOSTIC POSSIBILITIES FOR ASTHMA
Infants and Children
Upper airway diseases
Allergic rhinitis and sinusitis
Obstructions involving large airways
Foreign body in trachea or bronchus
Vocal cord dysfunction
Vascular rings or laryngeal webs
Laryngotracheomalacia, tracheal stenosis, or bronchostenosis
Enlarged lymph nodes or tumor
Obstructions involving small airways
Viral bronchiolitis or obliterative bronchiolitis
Cystic fibrosis
Bronchopulmonary dysplasia
Heart disease
Other causes
Diagnosed recurrent cough not due to asthma
Aspiration from swallowing mechanism dysfunction or gastroesophageal reflux
Adults
COPD (e.g., chronic bronchitis or emphysema)

Congestive heart failure
Pulmonary embolism
Mechanical obstruction of the airways (benign and malignant tumors)
Pulmonary infiltration with eosinophilia
Cough secondary to drugs (e.g., angiotensin-converting enzyme (ACE) inhibitors)
Vocal cord dysfunction
(NAEPP 2007 [5a])
Page 15 of 36
Attachment 3
Formal Evaluation of Asthma Exacerbation Severity in ED or Urgent Care Setting

Mild
Moderate
Severe
Breathlessness
Symptoms
Guideline 4
Subset: Respiratory
Arrest Imminent
While walking
While at rest (infant:

softer, shorter cry,
difficulty feeding)
While at rest (infant:

stops feeding)
Can lie down
Prefers sitting
Sits upright
Talks in
Alertness
Sentences
Normal or may be
agitated
Phrases
Usually agitated
Words
Usually agitated
Cannot talk
Drowsy or confused
Respiratory rate
Normal or increased
Increased
Increased, often
>30/minute
Guide to rates of breathing in awake children:
Age
Normal Rate
< 2 months
< 60/minute
2 to 12 months
< 50/minute
1 to 5 years
< 40/minute
6 to 8 years
< 30/minute
Usually not
Commonly
Usually
Normal or decreased
Moderate, often only

end expiratory
Loud; throughout
exhalation
Minimal or absent
Pulse/minute (at initial

presentation)
Pulsus paradoxus
< 100
100 to 120
Loud, throughout
inspiration and
exhalation or may be
absent
> 120
Absent <10 mmHg
May be present
10 to 25 mmHg
Often present
> 25 mmHg (adult)
20 to 40 mmHg (child)
Absence suggests
respiratory muscle fatigue
PEF (peak expiratory

flow)
Percent predicted or
percent personal best
PaO2 (arterial oxygen
pressure, on room air)
and/or
PCO2 (partial pressure of
carbon dioxide)
SaO2 (oxygen saturation)
(on room air)
at sea level
> 70%
Approx. 40 to 69% or
Response to treatment
lasts < 2 hours
< 40%
Normal (test not

usually necessary)
> 60 mmHg (test not

usually necessary)
< 60 mmHg: possible

cyanosis
< 25%
Note: PEF testing may not
be needed in very severe
attacks
< 42 mmHg (test not

usually necessary)
> 95%
< 42 mmHg (test not

usually necessary)
90 to 95%
> 42 mmHg: possible

respiratory failure
< 90%
Use of accessory muscles;

suprasternal retractions;
nasal flaring; abdominal
breathing
Wheeze
Signs
Functional Assessment
While at rest
Paradoxical
thoracoabdominal
movement
Bradycardia
Hypercapnia (hypoventilation) develops more easily in young children than

in adolescents and adults.
The presence of several parameters, but not necessarily all, indicates the general classification of the exacerbation
Many of these parameters have not been systematically studied, especially as they correlate with each other and thus serve only as
general guides
Expert Panel Report 3: Diagnosis and Management of Asthma, 2007 (LocalConsensus [5], NAEPP 2007 [5a]).
Page 16 of 36
Emergency Department Management of Asthma Exacerbations Algorithm
Guideline 4
Attachment 4
Initial Assessment: Brief History, physical examination (auscultation, use of accessory muscles, heart rate, respiratory rate, pulse
oximetry), PEF or FEV1 (if performed), or Asthma score, oxygen saturation, and other tests as indicated
Mild: see Attachment 3 for
details of signs and
symptoms:
Speaks in sentences
Wheeze mild to moderate
(end expiratory)
Moderate: see Attachment 3

for details of signs and
symptoms:
Speaks in words
Wheeze loud (throughout
exhalation)
Mild
Oxygen to achieve SaO2 > 90%
Inhaled SABA by nebulizer or MDI
with valved holding chamber, up to 3
doses in 1st hour
Oral systemic corticosteroids if no
response or if patient recently took oral
systemic corticosteroids
Severe: see Attachment 3 for

details of signs and symptoms:
Speaks in phrases
Wheeze loud (throughout
inhalation or exhalation) or
absent
Moderate / Severe
Oxygen to achieve SaO2 > 90%
High-dose inhaled SABA by nebulizer or
MDI with valved holding chamber, every
10 to 20 minutes or continuously for 1
hour PLUS ipratropium
Oral systemic corticosteroids
Respiratory Arrest or Impending

Respiratory Failure:
see Attachment 3 for details of
signs and symptoms:
Cannot speak
Wheeze absent
Impending or Actual Respiratory Arrest
Support airway
100% O2
Continuous SABA
Intravenous corticosteroids
Consider Adjunct therapies (see Table 3)
Transfer to higher level of care
Repeat Assessment: Symptoms, physical examination, Asthma Score or PEF, FEV1 (if performed), oxygen saturation, other tests as
indicated
Moderate Exacerbation
Asthma Score, PEF or FEV1 (40 to 69%
predicted/personal best)
Inhaled SABA every 60 minutes
Oral systemic corticosteroids
Continue treatment 1 to 3 hours,
provided there is improvement; make
admit decision in < 4 hours
Good Response
Asthma Score, PEF or FEV1
(> 70%)
Response sustained at least 60
minutes after last treatment
No distress
Physical exam: normal
Discharge Home
Continue treatment with inhaled SABAs.
Continue course of oral systemic
corticosteroid.
Continue on ICS. For those not on long-term
control therapy, consider initiation of an ICS.
Patient education (e.g., review medications
including inhaler technique; review/initiate
action plan; recommend close medical followup and, whenever possible, environmental
control measures).
Before discharge, schedule follow-up
appointment with PCP and /or asthma
specialist in 1-5 days.
If unable to schedule from ED, notify PCP of
status
Severe Exacerbation
Asthma Score, PEF or FEV1 (<40% predicted/personal best)
History: high risk patient
No improvement after initial treatment
Oxygen
Nebulized SABA, hourly or continuous, plus ipratropium
Oral systemic corticosteroids (see Table 2)
Consider adjunct therapies (see Table 3)
Incomplete Response
Unchanging Asthma Score,
PEF or FEV1 (40 69%)
Symptoms persist
Poor Response
Unchanging or worsening
Asthma Score, PEF or FEV1
(< 40%)
Symptoms worsening
Decide patients disposition

Admit to Hospital Ward
Oxygen as needed
Inhaled SABA
Systemic (oral or intravenous)
corticosteroid
Consider adjunct therapies
Monitor vital signs, Asthma Score,
PEF or FEV1, SaO2
Improve
Transfer to higher level

of care
Adapted from the National Heart Blood and Lung

Institute, National Education and Prevention
Program Expert Panel Report 3:
Diagnosis and Management of Asthma, 2007
(LocalConsensus [5], NAEPP 2007 [5a],
WorldHealthOrganizationWritingGroup 2006 [5a]).
Page 17 of 36
Severity Classification
Guideline 4
Attachment 5
(NAEPP 2007 [5a])
Page 18 of 36
Guideline 4
Attachment 5
Severity Classification (continued)
(NAEPP 2007 [5a])
Page 19 of 36
How to Control What Makes Your Asthma Worse
Guideline 4
Attachment 6
You can help prevent asthma episodes by staying away from things that make your asthma worse. This guide suggests
many ways to help you do this. You need to find out what makes your asthma worse. Some things that make asthma
worse for some people are not a problem for others. You do not need to do all of the things listed in this guide. Look
at the things listed below and put a check next to the ones that you know make your asthma worse, particularly if you
are allergic to those things. Then decide with your doctor what steps you will take. Start with the things in your
bedroom that bother your asthma. Try something simple first.
Tobacco Smoke
If you smoke, ask your doctor for ways to help you quit. Ask family members to quit smoking, too.
Do not allow smoking in your home, car, or around you.
Be sure no one smokes at a childs daycare center or school.
Smoke, Strong Odors, and Sprays
If possible, do not use a wood-burning stove, kerosene heater, fireplace, unvented gas stove, or heater.
Try to stay away from strong odors and sprays, such as perfume, talcum powder, hair spray, paints, new
carpet, or particle board.
Dust Mites
Many people who have asthma are allergic to dust mites. Dust mites are like tiny bug
s you cannot see that live in
cloth or carpet. Things that will help the most:
Encase your mattress in a special dust mite proof cover.
Encase your pillow in a special dust mite-proof cover or wash the pillow each week in hot water. Water must
be hotter than 130 F to kill the mites. Cooler water used with detergent and bleach can also be effective.
Wash the sheets and blankets on your bed each week in hot water.
Cockroaches
Many people with asthma are allergic to the dried droppings and remains of cockroaches.
Keep all food out of your bedroom.
Keep food and garbage in closed containers (never leave food out).
Use poison baits, powders, gels, or paste (for example, boric acid) to eliminate cockroaches.
You can also use traps.
If a spray is used to kill roaches, stay out of the room until the odor goes away.
Other things that can help:
Reduce indoor humidity to or below 60 percent; ideally 3050 percent. Dehumidifiers or central air
conditioners can do this.
Try not to sleep or lie on cloth-covered cushions or furniture.
Remove carpets from your bedroom and those laid on concrete, if you can.
Keep stuffed toys out of the bed, or wash the toys weekly in hot water or in cooler water with detergent and
bleach. Placing toys weekly in a dryer or freezer may help. Prolonged exposure to dry heat or freezing can kill
mites but does not remove allergen.
Animal Dander
Some people are allergic to the flakes of skin or dried saliva from animals.
The best thing to do:
Keep animals with fur or hair out of your home.
If you cant keep the pet outdoors, then:
Keep the pet out of your bedroom, and keep the bedroom door closed.
Remove carpets and furniture covered with cloth from your home. If that is not possible, keep the pet out
of the rooms where these are.
Expert Panel Report 3: Diagnosis and Management of Asthma, 2007 (NAEPP 2007 [5a]).
Page 20 of 36
How to Control What Makes Your Asthma Worse (continued)
Guideline 4
Attachment 6
You can help prevent asthma episodes by staying away from things that make your asthma worse. This guide suggests
many ways to help you do this. You need to find out what makes your asthma worse. Some things that make asthma
Indoor
worse
forMold
some people are not a problem for others. You do not need to do all of the things listed in this guide. Look
Fix
leaking
faucets,
othernext
sources
water.
at the things listed
below
andpipes
put a or
check
to theofones
that you know make your asthma worse, particularly if you
Clean
moldy
surfaces.
are allergic
to those
things.
Then decide with your doctor what steps you will take. Start with the things in your
basements,
possible.
bedroomDehumidify
that bother your
asthma.ifTry
something simple first.
VacuumSmoke
Cleaning
Tobacco
TrytoIfget
to vacuum
once
or twice
a week
yousomeone
smoke, else
ask your
doctorfor
foryou
ways
to help
you quit.
Ask family members to quit smoking, too.
If able:
Do not allow smoking in your home, car, or around you.
rooms
while
are being
vacuumed
for a short while afterward.
BeStay
sureout
no of
one
smokes
at athey
childs
daycare
center orand
school.
If unable:
Smoke, Strong Odors, and Sprays
Use a dust mask (from a hardware store), a central cleaner with a collecting bag outside the home, or a
If possible, do not use a wood-burning stove, kerosene heater, fireplace, unvented gas stove, or heater.
vacuum cleaner with a HEPA filter or a double-layered bag.
Try to stay away from strong odors and sprays, such as perfume, talcum powder, hair spray, paints, new
Pollen carpet,
and Outdoor
Mold
or particle
board.
During your allergy season (when pollen or mold spore counts are high)
Dust Mites
Try to keep your windows closed.
Many people who have asthma are allergic to dust mites. Dust mites are like tiny bug
s you cannot see that live in
If possible, stay indoors with windows closed during the midday and afternoon. Pollen and some mold spore
cloth or carpet. Things that will help the most:
counts are highest at that time.
Encase your mattress in a special dust mite proof cover.
Ask your doctor whether you need to take or increase anti-inflammatory medicine before your allergy season
Encase your pillow in a special dust mite-proof cover or wash the pillow each week in hot water. Water must
starts.
be hotter than 130 F to kill the mites. Cooler water used with detergent and bleach can also be effective.
Exercise or Sports
(NAEPP 2007 [5a])
Wash the sheets and blankets on your bed each week in hot water.
You should be able to be active without symptoms. See your doctor if you have asthma symptoms when you
are activesuch as when you exercise, do sports, play, or work hard.
Cockroaches
Ask with
your asthma
doctor about
takingtomedicine
you exercise
to prevent
symptoms.
Many people
are allergic
the driedbefore
droppings
and remains
of cockroaches.
Warm
forout
a period
before
you exercise.
Keep
all up
food
of your
bedroom.
Check
theand
air garbage
quality index
and containers
try not to work
orleave
play hard
Keep
food
in closed
(never
food outside
out). when the air pollution or pollen levels (if
allergic
to powders,
the pollen)
are or
high.
you
Useare
poison
baits,
gels,
paste (for example, boric acid) to eliminate cockroaches.
You can also use traps.
Seasonal Exposures
If a spray is used to kill roaches, stay out of the room until the odor goes away.
Maintain good hand-washing habits
Avoid
exposure
to crowds during high viral seasons, as much as is possible
Other things
that
can help:
Discuss
with your
healthcare
provide
benefits
of a 3050
seasonal
influenza
vaccine
Reduce
indoor
humidity
to or below
60 the
percent;
ideally
percent.
Dehumidifiers
or central air
conditioners can do this.
Things
Try not That
to sleep
or Make
lie on cloth-covered
cushions or furniture.
Other
Can
Asthma Worse
Sulfitescarpets
in foods:
Doyour
not drink
beerand
or wine
eaton
shrimp,
driedif fruit,
or processed potatoes if they cause
Remove
from
bedroom
thoseorlaid
concrete,
you can.
symptoms.
asthma
Keep stuffed
toys out of the bed, or wash the toys weekly in hot water or in cooler water with detergent and
bleach.
Cold air:
Covertoys
your
nose and
with
a scarf
onhelp.
cold Prolonged
or windy days.
Placing
weekly
in amouth
dryer or
freezer
may
exposure to dry heat or freezing can kill
mites
Otherbut
medicines:
Tell
your
doctor
about
all
the
medicines
you
may
take.
Include cold medicines, aspirin,
does not remove allergen.
herbal or alternative medicines, and even eye drops.
Animal Dander
Some people are allergic to the flakes of skin or dried saliva from animals.
The best thing to do:
Keep animals with fur or hair out of your home.
If you cant keep the pet outdoors, then:
Keep the pet out of your bedroom, and keep the bedroom door closed.
Remove carpets and furniture covered with cloth from your home. If that is not possible, keep the pet out
of the rooms where these are.
Expert Panel Report 3: Diagnosis and Management of Asthma, 2007 (NAEPP 2007 [5a]).
Page 21 of 36
How to Use Your Metered-Dose Inhaler
Guideline 4
Attachment 7
Using an inhaler seems simple, but most people do not use it the right way. When an inhaler is used the wrong
way, less medicine gets to the lungs. Use of a holding chamber/spacer increases reliability of drug effectiveness,
especially when inhalers are not used correctly.
For the next few days, read these steps aloud as you do them or ask someone to read them to you. Ask your
primary care provider to check how well you/your child are using the inhaler.
Use the inhaler in the way pictured below.
Steps for using your inhaler:
Getting ready 1. Take off the cap, shake the inhaler and attach spacer
2. Breathe out all the way.
3. Hold the inhaler the way instructed by your primary care provider (see picture).
4. Press down on the inhaler, within 5 seconds, begin to breathe in slowly through your
mouth.
5. Keep breathing in slowly, as deeply as possible.
6. Hold your breath and count to 10 slowly, if possible.
7. Remove the inhaler and breathe out through pursed lips (like blowing out a candle)
8. For inhaled quick-relief medicine (beta2-agonists), wait about 1 minute between puffs.
There is no need to wait between puffs for other medicines.
Clean your inhaler as needed, and know when to replace your inhaler. For instructions, read the package insert or
talk to your primary care provider or pharmacist. It is important to refill your prescription before the medicine
runs out or the inhaler expires to ensure medicine is available when needed.
Expert Panel Report 3: Diagnosis and Management of Asthma, 2007 (Roller 2007 [4a], LocalConsensus [5], NAEPP 2007 [5a]).
Page 22 of 36
Guideline 4
Attachment 8
Peak Flow Use
(NAEPP 2007 [5a])
Page 23 of 36
Guideline 4
Attachment 8
Peak Flow Use (continued)
(NAEPP 2007 [5a])
Page 24 of 36
Guideline 4
Attachment 9
Stepwise Approaching to Managing Asthma in Children 0 to 4 years of age
(NAEPP 2007 [5a])
Page 25 of 36
Guideline 4
Attachment 9
Stepwise Approaching to Managing Asthma in Children 5 to 11 years of age
(NAEPP 2007 [5a])
Page 26 of 36
Members of Asthma Team 2010

Community Physicians
Scott Callahan, MD, Co-Chair (General Pediatrics)
William DeBuys, MD (General Pediatrics)
CCHMC Physicians
Carolyn Kercsmar, MD, Co-Chair (Allergy and Pulmonary
Medicine)
Jeffrey Simmons, MD, Methodologist (General Pediatrics)
*Michele Lierl, MD (Allergy and Pulmonary Medicine)
Craig Gosdin, MD (General Pediatrics)
Laurie Johnson, MD (Emergency Medicine)
Sue Poynter, MD (Critical Care Medicine)
Rajit Basu, MD (Critical Care Medicine)
Residents
Angela Statile, MD (Chief Resident)
Corrine Bria, MD (Chief Resident)
Nursing
Sue Wieser, RN
Lisa Crosby, RN
Pharmacy
Bradley McCrory, PharmD
Michelle Caruso, PharmD, BCPS
Respiratory Therapy
Edward Conway, RRT (Certified Asthma Educator)
Lisa Devoto, RN, RT, CPN (Certified Asthma Educator)
Rachel Keller, RRT, RPFT (Certified Asthma Educator)
James M. Anderson Center (AC) - Support
*Eloise Clark, MPH, MBA (Lead Program Administrator)
*Wendy Gerhardt, MSN, RN-BC (Program Administrator)
Danette Stanko-Lopp, MA, MPH (Epidemiologist)
Karen Vonderhaar, RN, MSN (Program Administrator)
Ad hoc Advisors
Lorie Ferenzi, (Allergy and Pulmonary Medicine)
*Richard Ruddy, MD (Director, Emergency Medicine)
*Amal Assa'ad, MD (Allergy)
Karen McDowell, MD (Pulmonary Medicine)
Christopher J Cates, Division of Population Hlth Sci and Educ, St.
Georges, U of London, UK
Annie Lintzenich, MD, Gen Peds, Med U of SC
Ronald J Teufel II, MD, MSCR, Pediatrics/Internal Medicine, Gen
Peds Hospital Section, Med U of SC
*Member of 2002 Development Team
Development Process
The process by which this guideline was developed is documented in
the Guideline Development Process Manual; relevant development
materials are kept electronically. The recommendations contained in
this guideline were formulated by an interdisciplinary working group
which performed systematic search and critical appraisal of the
literature, using the Table of Evidence Levels described following the
references, and examined current local clinical practices.
To select evidence for critical appraisal for this guideline, the
Medline, EmBase and the Cochrane databases were searched for
dates of January, 2002 to November, 2009 to generate an unrefined,
combined evidence database using a search strategy focused on

answering clinical questions relevant to acute exacerbation of
asthma and employing a combination of Boolean searching on
human-indexed thesaurus terms (MeSH headings using an OVID
Medline interface) and
natural language searching on words in
Guideline 4
the title, abstract, and indexing terms. The citations were reduced
by: eliminating duplicates, review articles, non-English articles,
and adult articles. The resulting abstracts were reviewed by a
methodologist to eliminate low quality and irrelevant citations.
During the course of the guideline development, additional clinical
questions were generated and subjected to the search process, and
some relevant review articles were identified. September, 2002 was
the last date for which literature was reviewed for the previous
version of this guideline. The details of that review strategy are
documented and maintained in an asthma literature binder.
However, all previous citations were reviewed for appropriateness
to this revision. Any new literature encountered for this October,
2010 version was reviewed by two or more team members and then
discussed as a team.
Experience with the implementation of earlier publications of this
guideline has provided learnings which have been incorporated into
this revision.
Once the guideline has been in place for five years, a team
reconvenes to explore the continued validity of the guideline. This
phase can be initiated at any point that evidence indicates a critical
change is needed.
The guideline was externally appraised by three reviewers using the
AGREE instrument and the results by domain are:
Scope and Purpose

100%
Stakeholder Involvement 86%
Rigor of Development
92%
Clarity and Presentation

97%
Applicability
74%
Editorial Independence
72%
Recommendations have been formulated by a consensus process
directed by best evidence, patient and family preference and
clinical expertise. During formulation of these recommendations,
the team members have remained cognizant of controversies and
disagreements over the management of these patients. They have
tried to resolve controversial issues by consensus where possible
and, when not possible, to offer optional approaches to care in the
form of information that includes best supporting evidence of
efficacy for alternative choices.
The guideline has been reviewed and approved by clinical experts
not involved in the development process, distributed to senior
management, and other parties as appropriate to their intended
purposes.
The guideline was developed without external funding. All Team
Members and AC Support staff listed, have declared whether they
have any conflict of interest and none were identified.
Copies of this Evidence-based Care Guideline (EBCG) and any
available implementation tools are available online and may be
distributed by any organization for the global purpose of improving
child health outcomes. Website address:
http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/evbased/default.htm
Examples of approved uses of the EBCG include the following:
copies may be provided to anyone involved in the organizations
process for developing and implementing evidence-based care
guidelines;
hyperlinks to the CCHMC website may be placed on the
organizations website;
the EBCG may be adopted or adapted for use within the
organization, provided that CCHMC receives appropriate
attribution on all written or electronic documents; and
copies may be provided to patients and the clinicians who manage
their care.
Page 27 of 36
Guideline 4
Notification of CCHMC at HPCEInfo@cchmc.org for any EBCG, or

its companion documents, adopted, adapted, implemented or
hyperlinked by the organization is appreciated.
NOTE: These recommendations result from review of
literature and practices current at the time of their
formulations. This guideline does not preclude using care
modalities proven efficacious in studies published subsequent to
the current revision of this document. This document is not
intended to impose standards of care preventing selective
variances from the recommendations to meet the specific and
unique requirements of individual patients. Adherence to this
guideline is voluntary. The clinician in light of the individual
circumstances presented by the patient must make the ultimate
judgment regarding the priority of any specific procedure.
For more information about this guideline, its supporting
evidences and the guideline development process, contact the AC
office at: 513-636-2501 or HPCEInfo@cchmc.org .
Page 28 of 36
References
Note: When using the electronic version of this document,

indicates a hyperlink to the PubMed abstract. A hyperlink
following this symbol goes to the article PDF when the user is
within the CCHMC network
Guideline 4
12. Bhogal, S.; Zemek, R.; and Ducharme, F. M.: Written

action plans for asthma in children. Cochrane Database
of Systematic Reviews, 3: CD005306, 2006, [1a]
.
13. Blasi, F., and Johnston, S. L.: The role of antibiotics in
asthma. International Journal of Antimicrobial Agents,
.
29(5): 485-93, 2007, [5b]
14. Blitz, M.; Blitz, S.; Beasely, R.; Diner, B.; Hughes, R.;
Knopp, J. A.; and Rowe, B. H.: Inhaled magnesium
sulfate in the treatment of acute asthma. Cochrane
Database of Systematic Reviews, (4), 2009, [1b]
.
15. Boychuk, R. B. et al.: Change in approach and delivery of
medical care in children with asthma: results from a
multicenter emergency department educational asthma
management program. Pediatrics, 117(4 Pt 2): S145-51,
2006, [3a]
.
16. Boyd, M.; Lasserson, T. J.; McKean, M. C.; Gibson, P. G.;
Ducharme, F. M.; and Haby, M.: Interventions for
educating children who are at risk of asthma-related
emergency department attendance.[update of Cochrane
Database Syst Rev. 2001;(1):CD001290; PMID:
11279713]. Cochrane Database of Systematic Reviews,
.
(2): CD001290, 2009, [1a]
17. Boyd, R., and Stuart, P.: Pressurised metered dose inhalers
with spacers versus nebulisers for beta-agonist delivery in
acute asthma in children in the emergency department.
Emergency Medicine Journal, 22(9): 641-2, 2005, [3a]
.
18. Brand, P., Duiverman, EJ, Waalkens, HJ, vanEssenZandvliet, EEM, Kerrbijn, KF, & the Dutch CNSLD
Study Group: Peak flow variation in childhood asthma:
correlation with symptoms, airways obstruction, and
hyperresponsiveness during long term treatment with
inhaled corticosteroids. Thorax, 54: 103-107, 1999, [4a]
.
19. Brown, M. D.; Reeves, M. J.; Meyerson, K.; and
Korzeniewski, S. J.: Randomized trial of a
comprehensive asthma education program after an
emergency department visit.[see comment]. Annals of
Allergy, Asthma, & Immunology, 97(1): 44-51, 2006,
[2a]
.
20. Camargo, C. A., Jr.; Rachelefsky, G.; and Schatz, M.:
Managing asthma exacerbations in the emergency
department: summary of the National Asthma Education
and Prevention Program Expert Panel Report 3 guidelines
for the management of asthma exacerbations. Journal of
Emergency Medicine, 37(2 Suppl): S6-S17, 2009, [5b]
.
21. Canino, G.; Vila, D.; Normand, S.-L. T.; Acosta-Perez, E.;
Ramirez, R.; Garcia, P.; and Rand, C.: Reducing
asthma health disparities in poor Puerto Rican children:
the effectiveness of a culturally tailored family
intervention. Journal of Allergy & Clinical Immunology,
121(3): 665-70, 2008, [2a]
.
22. Carl, J. C.; Myers, T. R.; Kirchner, H. L.; and Kercsmar,
C. M.: Comparison of racemic albuterol and levalbuterol
for treatment of acute asthma. Journal of Pediatrics,
143(6): 731-6, 2003, [2a]
.
23. Castro-Rodriguez, J. A., and Rodrigo, G. J.: beta-agonists
through metered-dose inhaler with valved holding
chamber versus nebulizer for acute exacerbation of
wheezing or asthma in children under 5 years of age: a
systematic review with meta-analysis. Journal of
Pediatrics, 145(2): 172-7, 2004, [1a]
.
http://www.ncbi.nlm.n ih.gov/entrez/query.fcgi?cmd=Retr ieve&db=P ubMed&do pt=Citation&list_uid s=1 685609 0
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaBhogal2 006.pdf
http://www.ncbi.n lm.nih .gov/entrez /query.fcgi?cmd =Retr ieve&db=P ubMed&dopt=Cita tion &list_u ids =1735 3114
Akinbami, L. J.; Moorman, J. E.; Garbe, P. L.; and

Sondik, E. J.: Status of childhood asthma in the United
States, 1980-2007. Pediatrics, 123 Suppl 3: S131-45,
.
2009, [4a]
2. Allcock, D.: Using a community respiratory service to reduce

children's hospital admissions. Nursing Times, 105(4):
22-3, 2009, [4b]
.
3. Altamimi, S.; Robertson, G.; Jastaniah, W.; Davey, A.;
Dehghani, N.; Chen, R.; Leung, K.; and Colbourne,
M.: Single-dose oral dexamethasone in the emergency
management of children with exacerbations of mild to
moderate asthma. Pediatric Emergency Care, 22(12):
786-93, 2006, [2a]
.
4. Alter, H. J.; Koepsell, T. D.; and Hilty, W. M.: Intravenous
magnesium as an adjuvant in acute bronchospasm: a
meta-analysis. Annals of Emergency Medicine, 36(3):
191-7, 2000, [1a]
.
5. Altunc, U.; Pittler, M. H.; and Ernst, E.: Homeopathy for
childhood and adolescence ailments: systematic review
of randomized clinical trials. Mayo Clinic Proceedings,
82(1): 69-75, 2007, [1a]
.
6. Andrews, T.; McGintee, E.; Mittal, M. K.; Tyler, L.;
Chew, A.; Zhang, X.; Pawlowski, N.; and Zorc, J. J.:
High-dose continuous nebulized levalbuterol for pediatric
status asthmaticus: a randomized trial. Journal of
Pediatrics, 155(2): 205-10.e1, 2009, [2b]
.
7. Arshad, S. H.; Bateman, B.; Sadeghnejad, A.; Gant, C.;
and Matthews, S. M.: Prevention of allergic disease
during childhood by allergen avoidance: the Isle of Wight
prevention study. Journal of Allergy & Clinical
Immunology, 119(2): 307-13, 2007, [2a]
.
8. Bartlett, S. J., Kolodner, Kenneth, Butz, Arlene M,
Eggeston Peyton, Malveaux, Floyd J, Rand, Cynthia
S: Maternal Depressive Symptoms and Emergency
Department Use Among Innere-city Children with
Asthma Archives of Pediatrics & Adolescent Medicine,
155: 347-353, 2001, [3a]
.
9. Belamarich: Do Obeses Inner-City Children with Asthma
have more Symptoms than Nonobese Children with
Asthma? Pediatrics, 106(6): 1436-1441, 2000, [3a]
.
10. Bender, B.; Wamboldt, F. S.; O'Connor, S. L.; Rand, C.;
Szefler, S.; Milgrom, H.; and Wamboldt, M. Z.:
Measurement of children's asthma medication adherence
by self report, mother report, canister weight, and Doser
CT. Annals of Allergy, Asthma, & Immunology, 85(5):
416-21, 2000, [3b]
.
11. Benito-Fernandez, J.; Gonzalez-Balenciaga, M.; CapapeZache, S.; Vazquez-Ronco, M. A.; and Mintegi-Raso,
S.: Salbutamol via metered-dose inhaler with spacer
versus nebulization for acute treatment of pediatric
asthma in the emergency department. Pediatric
Emergency Care, 20(10): 656-9, 2004, [3a]
.
1.
http://www.ncbi.n lm.nih .gov/entrez /query.fcgi?cmd =Retrieve&db =PubMed &dop t=Citation &list_u ids =1922 1156
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaA kinbami2009. pdf
http://www.ncbi.n lm.nih .gov/entrez /query.fcgi?cmd =Retrieve&db =PubMed &dop t=Cita tion &list_u ids =1926 3772
http://ovidsp.ovid.com/ovidweb.cg i?T=JS&NEWS =N&PAGE =fulltext&A N=17198 210&D =medl
http://ovidsp. ovid.com/ovid web.cgi? T=JS &NEW S=N&PAG E=fulltext&AN=10 969219 &D=med4
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaAllcock2 009.pdf
http://groups/p2/E BC_ Files/Articles _Cited_in_A sthma/AsthmaAltamini2 006.PDF
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaAlter2000.pdf
http://www.ncb i.nlm. nih.gov/en trez/query.fcg i?cmd=Retrieve&db =PubMed&d o pt=Cita tion &list_u ids =1728 5788
http://groups /p2/E BC_Files/Articles_Cited_in_Asthma/As thmaAltunc2007.p df
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaAndrews2009.PDF
http://www.ncb i.nlm.n ih.gov/en trez/query.fcg i?cmd=Retrieve&db=PubMed&d opt=Citation&lis t_uid s=1 729185 1
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaArshad2007.pdf
http://www. ncbi.nlm. nih.gov/en trez/query. fcgi?cmd=Retrieve&db =Pub Med&dopt=Citation &lis t_uids=112318 00
http://groups/p2/E BC_ Files/Articles_ Cited_in_A sthma/AsthmaBartlett2001.p df
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaBelamarich2000.pdf
http://ovidsp.ovid.com/ovidweb.cg i?T=JS&NEWS =N&PAGE =fulltext&A N=11101 187&D =med4
http://grou ps/p 2/EBC_ Files /Articles_ Cited_ in_As thma/AsthmaBender2000.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaBenito- Fernandez2004. pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaBlitz2009.p df
http://groups /ce/EBC_Files/Articles_Cited_in _Asthma_ED/AsthmaBoy chu k2006. pdf
http://www.ncbi.nlm .nih.g ov/entrez/q uery.fcgi?cmd =Retrieve&db=Pu bMed&dop t=Citatio n&list_ uids =193 70563
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaBoy d2005.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaBrand1999. pdf
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaBlasi200 7.pdf
http://group s/ce/EBC_ Files/Ar ticles_ Cited_ in_Asthma_ED/AsthmaBoy d2009.pdf
http://gro ups/ce/E BC_ Files/Articles_ Cited_in_A sthma_ED/AsthmaBrown2006.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaCamargo2009.pdf
http://www. ncbi.nlm. nih.gov/en trez/query.fcg i?cmd=Retrieve&db=PubMed&d opt=Citation&lis t_uids=180616 48
http://ovidsp.ovid.com /ovidweb.cg i?T=JS&NEWS =N&PAGE =fullte xt&AN=1465 7817 &D=med4
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_A sthma/AsthmaCanin o2008.p df
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaCarl2003.pdf
http://www.ncbi.nlm.n ih.gov/entrez/query.fcgi?cmd=Retr ieve&db=P ubMed&do pt=Citation&list_uids =15 289762
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaCastro-Rodr iquez2 004.pdf
Page 29 of 36
24. Cates, C. J.; Crilly, J. A.; and Rowe, B. H.: Holding
chambers (spacers) versus nebulisers for beta-agonist
treatment of acute asthma.[update of Cochrane Database
Syst Rev. 2003;(3):CD000052; PMID: 12917881].
Cochrane Database of Systematic Reviews, (2):
.
CD000052, 2006, [1a]
25. Cates, C. J.; Lasserson, T. J.; and Jaeschke, R.: Regular

treatment with formoterol and inhaled steroids for
chronic asthma: serious adverse events. Cochrane
Database of Systematic Reviews, (2): CD006924, 2009a,
[1a]
.
26. Cates, C. J.; Lasserson, T. J.; and Jaeschke, R.: Regular
treatment with salmeterol and inhaled steroids for chronic
asthma: serious adverse events. Cochrane Database of
Systematic Reviews, (3): CD006922, 2009b, [1a]
.
27. Chan-Yeung, M., Ferguson, Alexander, Dimich-Ward,
Helen, Watson, Wade, Manfreda, Jure, Becker, Allan:
Effectiveness of and compliance to intervention measures
in reducing house dust and cat allergen levels Anals of
Allergy and Immunology 88: 52-58, 2002, [2a]
.
28. Chang, A. B.; Clark, R.; Sloots, T. P.; Stone, D. G.; Petsky,
H. L.; Thearle, D.; Champion, A. A.; Wheeler, C.;
and Acworth, J. P.: A 5- versus 3-day course of oral
corticosteroids for children with asthma exacerbations
who are not hospitalised: a randomised controlled trial.
Medical Journal of Australia, 189(6): 306-10, 2008, [2a]
.
29. Ciarallo, L.; Brousseau, D.; and Reinert, S.: Higher-dose
intravenous magnesium therapy for children with
moderate to severe acute asthma. Archives of Pediatrics
& Adolescent Medicine, 154(10): 979-83, 2000, [2b]
.
30. CMSA: Case Management Society of America
http://www.cmsa.org/, 2010, [5] .
31. Coffman, J. M.; Cabana, M. D.; Halpin, H. A.; and Yelin,
E. H.: Effects of asthma education on children's use of
acute care services: a meta-analysis. Pediatrics, 121(3):
575-86, 2008, [1a]
.
32. Cooper, W. O., Hickson, Gerald B: Corticsteroid
Prescription Filling for Children Covered by Medicaid
Following an Emergency Department Visit or a
Hospitalization for Asthma Archives of Pediatric
Adolescent Medicine, 155: 1111-1115, 2001, [4a]
.
33. Cope, S. F.; Ungar, W. J.; and Glazier, R. H.:
Socioeconomic factors and asthma control in children.
Pediatric Pulmonology, 43(8): 745-52, 2008, [4a]
.
34. Coughlan, J., Gibson, PG, Henry RL Medical Treatment for
reflux oesophaitis doesnot consistently improve asthma
control: a systematic review. Thorax, 56: 198-204, 2001,
[1a]
.
35. Custovic, A., Simpson, Bridget M, SImpson, Angela,
Kissen, Patricia, Woodcock, Ashley: Effect of
Environmental Manipulation in Pregnancy and early Life
on Respiratory Symptoms, and Atopy During First Year
of Life: a Randomized Trial. Lancet, 358: 188-193, 2001,
[2a]
.
36. D'Avila, R. S.; Piva, J. P.; Marostica, P. J. C.; and
Amantea, S. L.: Early administration of two intravenous
bolus of aminophylline added to the standard treatment of
children with acute asthma. Respiratory Medicine,
102(1): 156-61, 2008, [2b]
.
http://www. ncbi.nlm .nih.g ov/entrez/q uery.fcgi?cmd =Retrieve&db =PubMed&dopt=Cita tion &list_u ids =16625 527
http://ovidsp. ovid.com/ovid web.cgi? T=JS &NEW S=N&PAG E=fulltext&AN=19 370661 &D=medl
http://ovidsp.ovid.com/ovid web.cgi? T=JS &NEWS =N&PAGE =fu lltext&AN=195 88410 &D=med l
http://groups/p2/E BC_Files/Articles _Cited_in_A sthma/AsthmaCates20 06.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_A sthma/AsthmaCates200 9a.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaCates2009 b.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaChan-Yeng2002.p df
http://grou ps/ce/EBC_ Files /Articles_ Cited_ in_As thma_ED/AsthmaChang 2008.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaCiarallo20 00.PDF
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaCoffman2008.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaCooper2001 .pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaCope200 8.PDF
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaCoug hlan2001 .pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaCus tovic20 01.pdf
Guideline 4
37. Debley, J. S.; Carter, E. R.; Gibson, R. L.; Rosenfeld, M.;

and Redding, G. J.: The prevalence of ibuprofensensitive asthma in children: a randomized controlled
bronchoprovocation challenge study.[see comment].
Journal of Pediatrics, 147(2): 233-8, 2005, [1a]
.
38. Deerojanawong, J.; Manuyakorn, W.; Prapphal, N.;
Harnruthakorn, C.; Sritippayawan, S.; and
Samransamruajkit, R.: Randomized controlled trial of
salbutamol aerosol therapy via metered dose inhalerspacer vs. jet nebulizer in young children with wheezing.
Pediatric Pulmonology, 39(5): 466-72, 2005, [2b]
.
39. Delgado, A.; Chou, K. J.; Silver, E. J.; and Crain, E. F.:
Nebulizers vs metered-dose inhalers with spacers for
bronchodilator therapy to treat wheezing in children aged
2 to 24 months in a pediatric emergency department.
Archives of Pediatrics & Adolescent Medicine, 157(1):
76-80, 2003, [2a]
.
40. Dell, S. D.; Foty, R.; Becker, A.; Franssen, E.; and
Chapman, K. R.: Parent-reported symptoms may not be
adequate to define asthma control in children. Pediatric
Pulmonology, 42(12): 1117-24, 2007, [2a]
.
41. Dolovich, M. B. et al.: Device selection and outcomes of
aerosol therapy: Evidence-based guidelines: American
College of Chest Physicians/American College of
Asthma, Allergy, and Immunology. Chest, 127(1): 33571, 2005, [1a]
.
42. Dotson, K. M. D.; Dallman, M. M. D.; Bowman, C. M. M.
D.; and Titus, M. O. M. D.: Ipratropium Bromide for
Acute Asthma Exacerbations in the Emergency Setting:
A Literature Review of the Evidence. Pediatric
Emergency Care, 25(10): 687-692, 2009, [1b]
.
43. Douglas, J., Aroni, R, Oeman, D, Stewart, K, Sawyer, S,
Thien, F: A Qualitative Study of Asction Plans for
Asthma British Medical Journal, 324, 2002, [2b]
.
44. Dozier, A.; Aligne, C. A.; and Schlabach, M. B.: What is
asthma control? Discrepancies between parents'
perceptions and official definitions. Journal of School
Health, 76(6): 215-8, 2006, [4a]
.
45. Ebbinghaus, S., and Bahrainwala, A. H.: Asthma
management by an inpatient asthma care team. Pediatric
Nursing, 29(3): 177-83, 2003, [4b]
.
46. Edmonds, M.; Camargo, C. A.; Pollack, C. V.; and Rowe,
B. H.: Early use of inhaled corticosteroids in the
emergency department treatment of acute asthma.
Cochrane Database of Systematic Reviews, (4), 2009,
[1a]
.
47. FDA: New Safety Controls for Long-Acting Beta Agonists,
Medications used to Treat Asthma - News Release.
www.fda.gov/drugs/DrugSafety/InformationbyDrugClass
/ucm199565.htm, 2010, [5] .
48. Ferris, T. G., Crain, Ellen F, Oken, Emily, Wang, Linda,
Clark, Sunday, Camargo, Carlos A, : Insurance and
Quality of Care for Children with Acutre Asthma
Ambulatory Pediatrics 1(5): 267-274, 2001, [4a]
.
http://www.ncbi.nlm.n ih.gov/entrez/query.fcgi?cmd=Retr ieve&db=P ubMed&do pt= Citation&list_uid s=1 612605 6
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaDebley 2005.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaDeerojanawong2005.pdf
http://grou ps/p 2/EBC_ Files /Articles_ Cited_ in_As thma/AsthmaDelgado2003.p df
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaDell2007.pdf
http://ovidsp. ovid.com/ovid web.cgi? T=JS &NEW S=N&PAG E=fulltext&AN=15 654001 &D =med4
http://grou ps/p 2/EBC_ Files /Articles_Cited_in_A sthma/AsthmaDolov ich2005. pdf
http://ovidsp.ovid.com /ovidweb.cg i?T=JS&NEWS =N&PAGE =fulltext&A N=00006 565-
20091000 0-00018 &D=ovftjV NOvid TechnologiesD BJournals@Ovid
http://grou ps/p 2/EBC_ Files /Articles_ Cited_ in_As thma/AsthmaDotson 2009.PDF
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaDouglass20 02.pdf
http://www.ncb i.nlm.n ih.gov/entrez/query.fcg i?cmd=Retrieve&db=PubMed&do pt=Citation&lis t_uid s=1 691884 1
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaDozier2006. pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaEbinghaus2 003.pdf
http://gro ups/ce/E BC_ Files/Articles_ Cited_in_A sthma_ED/AsthmaEdmonds2009.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaFerris2001. pdf
http://gro ups/ce/E BC_ Files/Articles_ Cited_in_A sthma_ED/AsthmaD'Avila2008.pdf
Page 30 of 36
49. Ferris, T. G.; Kuhlthau, K.; Ausiello, J.; Perrin, J.; and
Kahn, R.: Are minority children the last to benefit from
a new technology? Technology diffusion and inhaled
corticosteriods for asthma. Medical Care, 44(1): 81-6,
.
2006, [4a]
50. Finn, P. W., Boudreau, Jacques O, Hongzhen, BS,

Yunsheng, Wang, Champman, MArtin D, Vincent,
Carey, Burge, Harriet A, Weiss, Scott T, Perkins,
David L, Gold, Diane R: Children at Risk for Asthma:
Home Allergen Levels, Lymphocyte Proliferation, and
Wheeze. Journal of Allergy & Clinical Immunology, 105:
933-942, 2000, [3a]
.
51. Flores, G.; Abreu, M.; Tomany-Korman, S.; and Meurer,
J.: Keeping children with asthma out of hospitals:
parents' and physicians' perspectives on how pediatric
asthma hospitalizations can be prevented. Pediatrics,
116(4): 957-65, 2005, [3a]
.
52. Forbis, S., Aligne, CA Poor Readability of Written Asthma
Management Plans Found in National Guidelines.
Pediatrics, 109(4), 2002, [2b]
.
53. Garbutt, J.; Highstein, G.; Nelson, K. A.; Rivera-Spoljaric,
K.; and Strunk, R.: Detection and home management of
worsening asthma symptoms. Annals of Allergy, Asthma,
& Immunology, 103(6): 469-73, 2009, [2a]
.
54. Geelhoed, G. L. L., ; Le Souef, PN: Evaluation of SaO2 as a
predictor of outcome in 280 children presenting with
acute asthma Annals of Emergency Medicine 23(6):
1236-41, 1994, [3a]
.
55. Ginde, A. A.; Espinola, J. A.; and Camargo, C. A., Jr.:
Improved overall trends but persistent racial disparities in
emergency department visits for acute asthma, 19932005.[see comment]. Journal of Allergy & Clinical
Immunology, 122(2): 313-8, 2008, [4a]
.
56. Goldberg, S., Springer, C, Avital, A, GOdfrey, S, BarYishay, E: Can Peak Expiratory Flow Measurmenets
Estimate Small Airway Function in Asthmatic Children?
. Chest, 120: 482-488, 2001, [4a]
.
57. Gordon, S.; Tompkins, T.; and Dayan, P. S.: Randomized
trial of single-dose intramuscular dexamethasone
compared with prednisolone for children with acute
asthma. Pediatric Emergency Care, 23(8): 521-7, 2007,
[2a]
.
58. Gorelick, M. H.; Stevens, M. W.; Schultz, T.; and
Scribano, P. V.: Difficulty in obtaining peak expiratory
flow measurements in children with acute asthma.
Pediatric Emergency Care, 20(1): 22-6, 2004, [3a]
.
59. Graham, V.; Lasserson, T. J.; and Rowe, B. H.: Antibiotics
for acute asthma. Cochrane Database of Systematic
Reviews, (4), 2009, [1a]
.
60. Greenberg, R. A.; Kerby, G.; and Roosevelt, G. E.: A
comparison of oral dexamethasone with oral prednisone
in pediatric asthma exacerbations treated in the
emergency department. Clinical Pediatrics, 47(8): 81723, 2008, [2b]
.
61. Gries, D. M.; Moffitt, D. R.; Pulos, E.; and Carter, E. R.: A
single dose of intramuscularly administered
dexamethasone acetate is as effective as oral prednisone
to treat asthma exacerbations in young children. Journal
of Pediatrics, 136(3): 298-303, 2000, [2b]
.
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaFerris2006 .pdf
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaFinn20 00.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_A sthma/AsthmaFlores2005.PDF
http://www.ncbi. nlm.n ih.gov/entrez/query.fcgi?cmd =Retr ieve&db=Pu bMed&dop t=Citatio n&list_ uids =119 27725
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaForbis2 002.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaGarbutt2009.p df
http://group s/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaGeelhood1994.p df
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaGinde2008.p df
http://www.ncbi.n lm.nih.gov/entrez /query.fcgi?cmd =Retr ieve&db=Pu bMed&dop t=Citatio n&list_ uids =115 02647
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaGordon200 7.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaGorelick2004.pdf
http://www.ncbi. nlm.nih.gov/entrez/query.fcgi?cmd =Retr ieve&db=Pu bMed&dop t=Citation&lis t_uid s=1 168702 2
http://ovidsp. ovid.com/ovid web.cgi? T=JS &NEW S=N&PAG E=fulltext&D=med l&A N=184676 73
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaGraham2009.pdf
http://gro ups/p 2/E BC_ Files/Articles_Cited_in_A sthma_ED/As thmaGreenberg2008.pdf
http://www.ncb i.nlm.n ih.gov/en trez/query.fcg i?cmd=Retrieve&db=PubMed&d opt=Citation& lis t_uid s=1 070068 4
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaGries2007.PDF
Guideline 4
62. Griffiths, C. et al.: Specialist nurse intervention to reduce

unscheduled asthma care in a deprived multiethnic area:
the east London randomised controlled trial for high risk
asthma (ELECTRA). British Medical Journal,
328(7432): 144, 2004, [2a]
.
63. Gupta, M. K., and Singh, M.: Evidence based review on
levosalbutamol. Indian Journal of Pediatrics, 74(2): 1617, 2007, [1b]
.
64. Gupta, R. S.; Carrion-Carire, V.; and Weiss, K. B.: The
widening black/white gap in asthma hospitalizations and
mortality. Journal of Allergy & Clinical Immunology,
117(2): 351-8, 2006, [4a]
.
65. Halterman, J. S.; McConnochie, K. M.; Conn, K. M.;
Yoos, H. L.; Kaczorowski, J. M.; Holzhauer, R. J.;
Allan, M.; and Szilagyi, P. G.: A potential pitfall in
provider assessments of the quality of asthma control.
Ambulatory Pediatrics, 3(2): 102-5, 2003, [4a]
.
66. Hardasmalani, M. D.; DeBari, V.; Bithoney, W. G.; and
Gold, N.: Levalbuterol versus racemic albuterol in the
treatment of acute exacerbation of asthma in children.
Pediatric Emergency Care, 21(7): 415-9, 2005, [2b]
.
67. Hayday, K., and Stevermer, J. J.: In children hospitalized
for asthma exacerbations, does adding ipratropium
bromide to albuterol and corticosteroids improve
outcome? Journal of Family Practice, 51(3): 280, 2002,
[5a]
.
68. Hondras, M. A.; Linde, K.; and Jones, A. P.: Manual
therapy for asthma.[update of Cochrane Database Syst
Rev. 2002;(4):CD001002; PMID: 12519548]. Cochrane
Database of Systematic Reviews, (2): CD001002, 2005,
[1a]
.
69. Huang, L., Shyur, SD., Wen, DC., Chang, YC., Ma, YC.,
Lin, SC., Wu, WC., Wu, JY.,: Prednisolone solution for
acute asthma. Acta Paediatric Taiwan, 48(5): 257-262,
2007, [2b]
.
70. Hussain-Rizvi, A.; Kunkov, S.; and Crain, E. F.: Does
parental involvement in pediatric emergency department
asthma treatment affect home management? Journal of
Asthma, 46(8): 792-5, 2009, [2b]
.
71. Jalba, M.-S.: Three generations of ongoing controversies
concerning the use of short acting beta-agonist therapy in
asthma: a review. Journal of Asthma, 45(1): 9-18, 2008,
[1b]
.
72. Jamalvi, S. W.; Raza, S. J.; Naz, F.; Shamim, S.; and
Jamalvi, S. M. Z.-u.-W.: Management of acute asthma
in children using metered dose inhaler and small volume
nebulizer. Journal of the Pakistan Medical Association,
56(12): 595-9, 2006, [3a]
.
73. Jenkins, C.; Costello, J.; and Hodge, L.: Systematic review
of prevalence of aspirin induced asthma and its
implications for clinical practice.[see comment]. British
Medical Journal, 328(7437): 434, 2004, [1a]
.
74. Johnson, K. B.; Blaisdell, C. J.; Walker, A.; and Eggleston,
P.: Effectiveness of a clinical pathway for inpatient
asthma management. Pediatrics, 106(5): 1006-12, 2000,
[2a]
.
75. Jones, K. G., Bell J, Fehrenbach, C, Pearce, L, Grimley, D,
McCarthy, TP, : Understanding Patient Perceptions of
Asthma: Results of the Asthma Control and Expectations
(ACE) Survey. Interanational Journal of Clinical
Practice, 56(2): 89-93, 2002, [2a]
.
http://www.ncbi.n lm.nih.gov/entrez /query.fcgi?cmd =Retrieve&db=Pu bMed&dop t=Citation&list_uids =14 718266
http://groups /p2/EBC_Files/Articles_ Cited_in_A sthma/AsthmaGupta200 7.PDF
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaHardasmalani2005.PDF
http://ovidsp. ovid.com/ovid web.cgi? T=JS &NEW S=N&PAG E=fulltext&AN=11 978242 &D=med4
http://group s/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaGriffiths2004 .pdf
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaGupta;Carrion200 6.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaHay day 2001.PDF
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaHondras2005. pdf
http://groups /p2/E BC_Files/Articles _Cited_in_A sthma/AsthmaHuang200 7.pdf
http://ovids p.ovid.com/ovidweb.cgi?T=JS&NEWS =N&PAGE =fulltext&A N=198632 82&D =medl
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaHussain_ Riv zi20 09.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaJamalvi2006.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaJen kins2 004.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaJohns on2000. pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaJones2002.p df
Page 31 of 36
76. Jones, R.; Lin, S.; Munsie, J. P.; Radigan, M.; and Hwang,
S.-A.: Racial/ethnic differences in asthma-related
emergency department visits and hospitalizations among
children with wheeze in Buffalo, New York. Journal of
Asthma, 45(10): 916-22, 2008, [4a]
.
77. Kamble, S., and Bharmal, M.: Incremental direct
expenditure of treating asthma in the United States.
Journal of Asthma, 46(1): 73-80, 2009, [4a]
.
78. Kamps, A. W. A.; Roorda, R. J.; and Brand, P. L. P.: Peak
flow diaries in childhood asthma are unreliable. Thorax,
.
56(3): 180-182, 2001, [2b]
79. Kanabar, D.: Ibuprofen and asthma in paediatric populations:

clinical concern or clinical reality? Journal of the Royal
Society of Medicine, 100 Suppl 48: 15-7, 2007, [1a]
.
80. Karimi, M.; Mirzaei, M.; and Ahmadieh, M. H.:
Acetaminophen use and the symptoms of asthma, allergic
rhinitis and eczema in children. Iranian Journal of
Allergy Asthma & Immunology, 5(2): 63-7, 2006, [4a]
.
81. Karnick, P.; Margellos-Anast, H.; Seals, G.; Whitman, S.;
Aljadeff, G.; and Johnson, D.: The pediatric asthma
intervention: a comprehensive cost-effective approach to
asthma management in a disadvantaged inner-city
community. Journal of Asthma, 44(1): 39-44, 2007, [2a]
.
82. Kaushal, R.; Bates, D. W.; Abramson, E. L.; Soukup, J.
R.; and Goldmann, D. A.: Unit-based clinical
pharmacists' prevention of serious medication errors in
pediatric inpatients. American Journal of Health-System
Pharmacy, 65(13): 1254-60, 2008, [3a]
.
83. Kayani, S., and Shannon, D. C.: Adverse Behavioral Effects
of Treatment for Acute Exacerbation of Asthma in
Children. Chest, 122(2): 624, 2002, [2b]
.
84. Keahey, L.; Bulloch, B.; Becker, A. B.; Pollack, C. V., Jr.;
Clark, S.; Camargo, C. A., Jr.; and Multicenter
Asthma Research Collaboration, I.: Initial oxygen
saturation as a predictor of admission in children
presenting to the emergency department with acute
asthma. Annals of Emergency Medicine, 40(3): 300-7,
2002, [3a]
.
85. Kelly, A.-M.; Kerr, D.; and Powell, C.: Is severity
assessment after one hour of treatment better for
predicting the need for admission in acute asthma?
Respiratory Medicine, 98(8): 777-81, 2004, [3a]
.
86. Kelly, C. S.; Andersen, C. L.; Pestian, J. P.; Wenger, A. D.;
Finch, A. B.; Strope, G. L.; and Luckstead, E. F.:
Improved outcomes for hospitalized asthmatic children
using a clinical pathway. Annals of Allergy, Asthma, &
Immunology, 84(5): 509-16, 2000, [4b]
.
87. Kim, I. K.; Phrampus, E.; Venkataraman, S.; Pitetti, R.;
Saville, A.; Corcoran, T.; Gracely, E.; Funt, N.; and
Thompson, A.: Helium/oxygen-driven albuterol
nebulization in the treatment of children with moderate to
severe asthma exacerbations: a randomized, controlled
trial. Pediatrics, 116(5): 1127-33, 2005, [2b]
.
http://www.ncbi.nlm.nih.g ov/entrez/query.fcgi?cmd =Retrieve&db =PubMed &dopt=Cita tion &list_u ids =19085 583
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaJones2008.p df
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaKamble2009.pdf
http://thor ax.bmj.com/cgi/content/abstract/5 6/3/1 80
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaKanabar2007.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaKarimi2006.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaKamps2001.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaKarnick20 07.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaKaushal2008.pdf
http://search.ebscohos t.com/lo gin.a spx?direct=true &db =a9h &AN=1025 8224 &log inpage =Lo gin.a sp&s ite=eho st-live&sco pe=site
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaKay ani2002.pdf
http://ovidsp.ovid.com/ovidweb.cg i?T=JS&NEWS =N&PAGE =fulltext&D =med4&AN=1219 2354
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaKeaney 2002pdf.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaKelly 2004.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaKelly 2000.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaKim2005.pdf
Guideline 4
88. Knudson, A.; Casey, M.; Burlew, M.; and Davidson, G.:
Disparities in pediatric asthma hospitalizations. Journal
of Public Health Management & Practice, 15(3): 232-7,
2009, [4a]
.
89. Lai, C. K. W.; Beasley, R.; Crane, J.; Foliaki, S.; Shah, J.;
Weiland, S.; International Study of, A.; and Allergies
in Childhood Phase Three Study, G.: Global variation
in the prevalence and severity of asthma symptoms:
phase three of the International Study of Asthma and
Allergies in Childhood (ISAAC).[see comment]. Thorax,
.
64(6): 476-83, 2009, [4a]
90. Lanphear, B. P., ALigne, C. Andrew, Auinger, Peggy,
Weitzman, Michael, Byrd, Robert S: Residential
Exposures Associated with Asthma in US Children.
Pediatrics, 107(3): 505-511, 2001b, [4a]
.
91. Lanphear, B. P., Kahn, Robert S, Berger, Omer, Auinger,
Peggy, Bortnick, Steven M, Nahhas, Ramzi W:
Contribution of Residential Exposures to Asthma in US
Children and Adolescents. Pediatrics, 107(6), 2001a,
[4a]
.
92. Lanski, S. L.; Greenwald, M.; Perkins, A.; and Simon, H.
K.: Herbal therapy use in a pediatric emergency
department population: expect the unexpected.
Pediatrics, 111(5 Pt 1): 981-5, 2003, [3a]
.
93. Lara, M.; Duan, N.; Sherbourne, C.; Halfon, N.;
Leibowitz, A.; and Brook, R. H.: Children's use of
emergency departments for asthma: persistent barriers or
acute need? Journal of Asthma, 40(3): 289-99, 2003, [2a]
.
94. Lavorini, F., and Fontana, G. A.: Targeting drugs to the
airways: The role of spacer devices. Expert Opinion on
Drug Delivery, 6(1): 91-102, 2009, [5b]
.
95. Lemanske, R. F., Jr. et al.: Step-up therapy for children with
uncontrolled asthma receiving inhaled corticosteroids.
New England Journal of Medicine, 362(11): 975-85,
2010, [2a]
.
96. Levy, M.; Heffner, B.; Stewart, T.; and Beeman, G.: The
efficacy of asthma case management in an urban school
district in reducing school absences and hospitalizations
for asthma. Journal of School Health, 76(6): 320-4, 2006,
[2a]
.
97. Lieu, T. A., Lozano, Paula, Finkelstein, Jonathan A, Chi,
Felicia W, Jensvold, Nancy G, Capra, Angela M,
Queensberry, Charles P, Selby, Joe V, Farber, Harold
J: Racial/Ethnic Variation in Asthma Status and
Management Practices Among Children in Managed
Medicaid. Pediatrics, 109(5): 857-865, 2002, [4a]
.
98. LocalConsensus, [5] .
99. Mansour, M. E.: How do we support follow-up with the
primary care provider after an emergency department
visit for asthma?[comment]. Pediatrics, 124(4): 1206-7,
2009, [5a]
.
100. Mansour, M. E.; Lanphear, B. P.; and DeWitt, T. G.:
Barriers to asthma care in urban children: parent
perspectives. Pediatrics, 106(3): 512-9, 2000, [2b]
.
101. Mark, J. D.: Integrative medicine and asthma. Pediatric
Clinics of North America, 54(6): 1007-23; xii, 2007, [1b]
.
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaKnudson 2009.p df
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaLai2009.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaLanphear2001b.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaLanphear2001a.pdf
http://group s/ce/EBC_ Files/Ar ticles_ Cited_ in_Asthma_ED/AsthmaLans ki20 03.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaLara2003.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaLavorini2009. pdf
http://www.ncb i.nlm.n ih.gov/en trez/query.fcg i?cmd=Retrieve&db=PubMed&d opt =Citation&lis t_uid s=1 691886 3
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaLevy 2006.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaLieu2002.p df
http://ovidsp.ovid.com/ovid web.cgi? T=JS &NEWS =N&PAGE =fu lltext&D=med4 &AN=10 969096
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaLamanske2010.PD F
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaMansour200 9.pdf
http://group s/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaMansour2000 .pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaMark2 007.pdf
Page 32 of 36
102. Martin, J.; Donaldson, A. N. A.; Villarroel, R.; Parmar, M.
K. B.; Ernst, E.; and Higginson, I. J.: Efficacy of
acupuncture in asthma: systematic review and metaanalysis of published data from 11 randomised controlled
trials. European Respiratory Journal, 20(4): 846-52,
2002, [1a]
.
103. Mathew, J. L., and Singh, M.: Metered dose inhaler with
spacer in children with acute asthma. Indian Pediatrics,
45(4): 295-7, 2008, [1b ]
.
104. McCarney, R. W.; Brinkhaus, B.; Lasserson, T. J.; and
Linde, K.: Acupuncture for chronic asthma. Cochrane
Database of Systematic Reviews, (1), 2009, [1a]
.
105. McDaniel, M.; Paxson, C.; and Waldfogel, J.: Racial
disparities in childhood asthma in the United States:
evidence from the National Health Interview Survey,
1997 to 2003. Pediatrics, 117(5): e868-77, 2006, [4a]
.
106. McDowell, K. M.; Chatburn, R. L.; Myers, T. R.;
O'Riordan, M. A.; and Kercsmar, C. M.: A costsaving algorithm for children hospitalized for status
asthmaticus. Archives of Pediatrics & Adolescent
Medicine, 152(10): 977-84, 1998, [2a]
.
107. McMullen, A. H.; Yoos, H. L.; and Kitzman, H.: Peak flow
meters in childhood asthma: parent report of use and
perceived usefulness. Journal of Pediatric Health Care,
16(2): 67-72, 2002, [2a]
.
108. Mitra, A. A. D.; Bassler, D.; Watts, K.; Lasserson, T. J.;
and Ducharme, F. M.: Intravenous aminophylline for
acute severe asthma in children over two years receiving
inhaled bronchodilators. Cochrane Database of
Systematic Reviews, (4), 2009, [1a]
.
109. MMWR Moorman, J. E. et al.: National surveillance for
asthma--United States, 1980-2004. Morbidity &
Mortality Weekly Report, Surveillance Summaries. 56(8):
.
1-54, 2007, [4a]
110. Mohammed, S., and Goodacre, S.: Intravenous and

nebulised magnesium sulphate for acute asthma:
systematic review and meta-analysis. Emergency
Medicine Journal, 24(12): 823-30, 2007, [1a]
.
111. Morgan, W. J. et al.: Results of a home-based environmental
intervention among urban children with asthma. New
England Journal of Medicine, 351(11): 1068-80, 2004,
[2a]
.
112. NAEPP: Expert Panel Report 3 (EPR-3): Guidelines for the
Diagnosis and Management of Asthma-Summary Report
2007.[erratum appears in J Allergy Clin Immunol. 2008
Jun;121(6):1330]. Journal of Allergy & Clinical
Immunology, 120(5 Suppl): S94-138, 2007, [5a]
.
113. Nakanishi, A. K.; Klasner, A. K.; and Rubin, B. K.: A
randomized controlled trial of inhaled flunisolide in the
management of acute asthma in children.[see comment].
Chest, 124(3): 790-4, 2003, [2b]
.
114. Nelson, H. S.; Weiss, S. T.; Bleecker, E. R.; Yancey, S. W.;
Dorinsky, P. M.; and Group, S. S.: The Salmeterol
Multicenter Asthma Research Trial: a comparison of
usual pharmacotherapy for asthma or usual
pharmacotherapy plus salmeterol.[Erratum appears in
Chest. 2006 May;129(5):1393]. Chest, 129(1): 15-26,
2006, [2a]
.
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaMartin20 02.pdf
http://www.ncbi.nlm.n ih.gov/entrez/query.fcgi?cmd=Retr ieve&db=P ubMed&dopt=Cita tion &list_u ids =1845 1447
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaMcCarney 2009.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaMcDaniel2006.p df
http://groups /p2/E BC_Files/Articles_Cited_in_Asthma/AsthmaMathew2008.pdf
http://ovidsp.ovid .com/ovid web.cgi? T=JS &NEWS =N&PAGE =fu lltext&D=med4 &AN=979 0607
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaMcDowell1998. pdf
http://www.ncb i.nlm. nih.gov/en trez/query.fcg i?cmd=Retrieve&db =PubMed&d o pt=Cita tion &list_u ids =1190 4640
http://groups /p2/E BC_Files/Articles_Cited_in_Asthma/As thmaMcMullen20 02.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaMitra2009.p df
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaMohammed2007.pdf
http://grou ps/p2/E BC_Files/Articles_Cited_i n_Asthma/As thmaMMWR20 04.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaMorgan2004 .pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaNAEPPExpertPanel3Exac2007.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaNakanis hi200 3.pdf
Guideline 4
115. Newman, S. P.: Spacer devices for metered dose inhalers.

Clinical Pharmacokinetics, 43(6): 349-60, 2004, [5a]
.
116. Ng, D. K. K.; Chow, P.-Y.; Lai, W.-P.; Chan, K.-C.; And,
B.-L. T.; and So, H.-Y.: Effect of a structured asthma
education program on hospitalized asthmatic children: a
randomized controlled study. Pediatrics International,
.
48(2): 158-62, 2006, [2a]
117. Norton, S. P.; Pusic, M. V.; Taha, F.; Heathcote, S.; and
Carleton, B. C.: Effect of a clinical pathway on the
hospitalisation rates of children with asthma: a
prospective study. Archives of Disease in Childhood,
.
92(1): 60-6, 2007, [4a]
118. Plotnick, L., and Ducharme, F.: Combined inhaled

anticholinergics and beta2-agonists for initial treatment
of acute asthma in children. Cochrane Database of
Systematic Reviews, (4), 2009, [1a]
.
119. Portnoy, J. M., and Jennings, D.: Utilization patterns in an
asthma intervention. Annals of Allergy, Asthma, &
Immunology, 97(1 Suppl 1): S25-30, 2006, [4a]
.
120. Qureshi, F.; Zaritsky, A.; and Poirier, M. P.: Comparative
efficacy of oral dexamethasone versus oral prednisone in
acute pediatric asthma. Journal of Pediatrics, 139(1): 206, 2001, [2a]
.
121. Qureshi, F.; Zaritsky, A.; Welch, C.; Meadows, T.; and
Burke, B. L.: Clinical efficacy of racemic albuterol
versus levalbuterol for the treatment of acute pediatric
asthma. Annals of Emergency Medicine, 46(1): 29-36,
2005, [3a]
.
122. Ralston, M. E.; Euwema, M. S.; Knecht, K. R.; Ziolkowski,
T. J.; Coakley, T. A.; and Cline, S. M.: Comparison of
levalbuterol and racemic albuterol combined with
ipratropium bromide in acute pediatric asthma: a
randomized controlled trial. Journal of Emergency
Medicine, 29(1): 29-35, 2005, [2a]
.
123. Reznik, M.; Ozuah, P. O.; Franco, K.; Cohen, R.; and
Motlow, F.: Use of complementary therapy by
adolescents with asthma. Archives of Pediatrics &
Adolescent Medicine, 156(10): 1042-4, 2002, [3a]
.
124. Ribeiro de Andrade, C.; Duarte, M. C.; and Camargos, P.:
Correlations between pulse oximetry and peak expiratory
flow in acute asthma. Brazilian Journal of Medical &
Biological Research, 40(4): 485-90, 2007, [3a]
.
125. Rich, M.; Lamola, S.; Amory, C.; and Schneider, L.:
Asthma in Life Context: Video Intervention/Prevention
Assessment (VIA). Pediatrics, 105(3): 469, 2000, [3b]
.
126. Rivera, M. L.; Kim, T. Y.; Stewart, G. M.; Minasyan, L.;
and Brown, L.: Albuterol nebulized in heliox in the
initial ED treatment of pediatric asthma: a blinded,
randomized controlled trial. American Journal of
Emergency Medicine, 24(1): 38-42, 2006, [2b]
.
127. Rodrigo, G. J., and Castro-Rodriguez, J. A.:
Anticholinergics in the treatment of children and adults
with acute asthma: a systematic review with metaanalysis. Thorax, 60(9): 740-6, 2005, [1a]
.
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaNewman2004.pdf
http://www.ncbi.n lm.nih .gov/entrez /query.fcgi?cmd =Retr ieve&db=PubMed &dop t=Citatio n&list_uids =16905 562
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaNG2006.pdf
http://groups/ce/E BC_Files/Artic les_Cited_in_ Asthma_ED/As thmaNorton2007.p df
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaPlotnic k2009 .pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaPortnoy 2006.pdf
http://groups /p2/EBC_Files/Articles_ Cited_in_A sthma/AsthmaQureshi200 1.pdf
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaQureshi2005.PD F
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaRalsto n2005.p df
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaRezn ik200 2.pdf
http://www.ncbi.nlm.n ih.gov/entrez/query.fcgi ?cmd=Retr ieve&db=P ubMed&do pt=Citation&list_uid s=1 740149 1
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaRibeiro.2 007.pdf
http://search.ebscohos t.com/log in.as px?direct=true&db=a9h&A N=2870 180&login page=Log in.asp &site=ehos t-live&scope =site
http://groups /p2/E BC_Files/Articles_Cited_in_Asthma/As thmaRich2000. pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaRivera2006.PD F
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaRodrigo2 005.pdf
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaNelson200 6.PDF
Page 33 of 36
128. Rodrigo, G. J.; Pollack, C. V.; Rodrigo, C.; and Rowe, B.
H.: Heliox for non-intubated acute asthma patients.
[1a]
.
129. Rodriguez, M. A., Winklleby, Marilyn A, Ahn, David,
Sunquist Jan, Kraemer, Helena C: Identification of
Population Subgroups of Children and Adolescents with
High Asthma Prevalence Archives of Pediatrics &
Adolescent Medicine, 156: 269-275, 2002, [4a]
.
130. Roller, C. M.; Zhang, G.; Troedson, R. G.; Leach, C. L.;
Le Souef, P. N.; and Devadason, S. G.: Spacer
inhalation technique and deposition of extrafine aerosol
in asthmatic children. European Respiratory Journal,
29(2): 299-306, 2007, [4a]
.
131. Rosen, C. M., and Rodriguez, L.: The Inner-City Asthma
Intervention asthma counselor program: a collaborative
model between physician and social worker to help
empower families. Annals of Allergy, Asthma, &
Immunology, 97(1 Suppl 1): S16-9, 2006, [4a]
.
132. Rowe, B., Spooner, C., Ducharme, F., Bretzlaff, J., Bota,
G.: Early emergency department treatment of acute
asthma with systemic corticosteroids [Systematic
Review]. Cochrane Database of Systematic Reviews, 1:
1, 2009a, [1a]
.
133. Rowe, B. H.; Bretzlaff, J.; Bourdon, C.; Bota, G.; Blitz, S.;
and Camargo, C. A.: Magnesium sulfate for treating
exacerbations of acute asthma in the emergency
department. Cochrane Database of Systematic Reviews,
(4), 2009b, [1a]
.
134. Salpeter, S. R.; Buckley, N. S.; Ormiston, T. M.; and
Salpeter, E. E.: Meta-analysis: effect of long-acting
beta-agonists on severe asthma exacerbations and
asthma-related deaths. Annals of Internal Medicine,
.
144(12): 904-12, 2006, [1a]
135. Salpeter, S. R.; Wall, A. J.; and Buckley, N. S.: Long-acting
beta-agonists with and without inhaled corticosteroids
and catastrophic asthma events. American Journal of
Medicine, 123(4): 322-8.e2, 2010, [1a]
.
136. Sanghera, N.; Chan, P.-Y.; Khaki, Z. F.; Planner, C.; Lee,
K. K. C.; Cranswick, N. E.; and Wong, I. C. K.:
Interventions of hospital pharmacists in improving drug
therapy in children: a systematic literature review. Drug
Safety, 29(11): 1031-47, 2006, [1a]
.
137. Scarfone, R. J.; Capraro, G. A.; Zorc, J. J.; and Zhao, H.:
Demonstrated use of metered-dose inhalers and peak
flow meters by children and adolescents with acute
asthma exacerbations.[see comment]. Archives of
Pediatrics & Adolescent Medicine, 156(4): 378-83, 2002,
[3b]
.
138. Schonberger, H. J. A. M.; Maas, T.; Dompeling, E.;
Knottnerus, J. A.; van Weel, C.; and van Schayck, C.
P.: Compliance of asthmatic families with a primary
prevention programme of asthma and effectiveness of
measures to reduce inhalant allergens--a randomized trial.
Clinical & Experimental Allergy, 34(7): 1024-31, 2004,
[2a]
.
139. Schreck, D. M., and Babin, S.: Comparison of racemic
albuterol and levalbuterol in the treatment of acute
asthma in the ED. American Journal of Emergency
Medicine, 23(7): 842-7, 2005, [4a]
.
http://group s/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaRodrigo 2009.p df
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaRodrig uez200 2.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_A sthma/AsthmaRoller2007.pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaRosen20 06.pdf
http://ovidsp.ovid.com/ovid web.cgi? T=JS &CS C=Y&NEWS =N&PAGE =fu lltext&D=coch&AN=0007 5320-100 000000-01 559
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaRower2009a.pdf
http://groups /ce/EBC_Files/Articles_Cited_in_Asthma_ED/As thmaRowe2009. pdf
http://www.ncbi.n lm.nih.gov/entrez /query.fcgi?cmd=Retrieve&db =PubMed &dopt=Cita tion &list_u ids =1675 4916
http://group s/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaSalpeter2006.p df
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaSalpeter2010.PDF
http://ovidsp.ovid.com/ovidweb.cgi? T=JS&NEWS=N&PAGE=fulltext&A N=170619 09&D =medl
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaSanghera2006.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaScarfone2002.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaSchonberger2004.p df
http://ovidsp.ovid.com/ovid web.cgi? T=JS &NEWS =N&PAGE =fu lltext&AN=162 91438 &D=med4
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaSchreck200 5.PDF
Guideline 4
140. Schuh, S.; Dick, P. T.; Stephens, D.; Hartley, M.; Khaikin,
S.; Rodrigues, L.; and Coates, A. L.: High-dose inhaled
fluticasone does not replace oral prednisolone in children
with mild to moderate acute asthma. Pediatrics, 118(2):
644-50, 2006, [2b]
.
141. Schulte, A.; Musolf, J.; Meurer, J. R.; Cohn, J. H.; and
Kelly, K. J.: Pediatric asthma case management: a
review of evidence and an experimental study design.
Journal of Pediatric Nursing, 19(4): 304-10, 2004, [1b]
.
142. Shalowitz, M. U., Berry, Carolyn A, Quinn, Kelly A, Wolf,
Raoul L: The Relationship of Life Stressores and
Maternal Depression to Pediatric Asthma Morbidity in a
Subspecialty Practice. Ambulatory Pediatrics, 1(4): 185193, 2001, [4a]
.
143. SIGN: British Guideline on the Management of Asthma:
Scottish Intercollegiate Guidelines Network Thorax, 63
Suppl 4: iv1-121, 2008, [5a]
.
144. Simons, F. E.; Roberts, J. R.; Gu, X.; and Simons, K. J.:
Epinephrine absorption in children with a history of
anaphylaxis. Journal of Allergy & Clinical Immunology,
101(1 Pt 1): 33-7, 1998, [2b]
.
145. Sin, D. D., and Man, S. F.: Low-dose inhaled corticosteroid
therapy and risk of emergency department visits for
asthma. Archives of Internal Medicine., 162(14): 1591-5,
2002, [4a]
.
146. Smith, L. A. et al.: Modifiable risk factors for suboptimal
control and controller medication underuse among
children with asthma. Pediatrics, 122(4): 760-9, 2008,
[4a]
.
147. Smith, M.; Iqbal, S. M. S. I.; Rowe, B. H.; and N'Diaye, T.:
Corticosteroids for hospitalised children with acute
asthma. Cochrane Database of Systematic Reviews, (4),
2009, [1a]
.
148. Sockrider, M. M.; Abramson, S.; Brooks, E.; Caviness, A.
C.; Pilney, S.; Koerner, C.; and Macias, C. G.:
Delivering tailored asthma family education in a pediatric
emergency department setting: a pilot study. Pediatrics,
117(4 Pt 2): S135-44, 2006, [2a]
.
149. Sole, D.; Komatsu, M. K.; Carvalho, K. V.; and Naspitz, C.
K.: Pulse oximetry in the evaluation of the severity of
acute asthma and/or wheezing in children. Journal of
Asthma, 36(4): 327-33, 1999, [2a]
.
150. Spiegel, J.; Love, A. S.; Wood, P. R.; Griffith, M.; Taylor,
K. R.; Williams, S. G.; and Redd, S. C.: The Inner-City
Asthma Intervention: description of a community-based
implementation of an evidence-based approach to asthma
management. Annals of Allergy, Asthma, & Immunology,
97(1 Suppl 1): S6-10, 2006, [4a]
.
151. Taketomo, C.; Hiodding, J.; and Kraus, D.: Pediatric
Dosage Handbook: Including Neonatal Dosing, Drug
Administration, & Extemporaneous Preparations, 16 Ed,
[5a] .
152. Travers, A.; Jones, A. P.; Kelly, K.; Barker, S. J.;
Camargo, C. A.; and Rowe, B. H.: Intravenous beta2agonists for acute asthma in the emergency department.
Cochrane Database of Systematic Reviews, (2):
CD002988, 2001, [1a]
.
153. Vidgren, M.; Paronen, P.; and A, K.: Effect of Extension
Devices on Drug Deposition from Inhalation Aerosols.
International Journal of Pharmaceutics, 39: 107-112,
1987, [4b]
.
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaSchuh2006 .pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaSchulte2004.pdf
http://www.ncbi.n lm.nih .gov/entrez /query.fcgi?cmd =Retrieve&db =PubMed &dop t=Citation &l ist_u ids =118 88399
http://groups/p2/E BC_ Files/Articles _Cited_in_A sthma/AsthmaShalowitz200 1.pdf
http://www.ncbi.nlm .nih.g ov/entrez/q uery.fcgi?cmd=Retrieve&db=P ubMed&do pt=Citation&lis t_uid s=1 846320 3
http://www.ncbi.n lm.nih.gov/entrez /qu ery.fcgi?cmd=Retr ieve&db=Pu bMed&dop t=Citatio n&list_ uids =944 9498
http://ovidsp. ovid.com/ovid web.cgi? T=JS &NEW S=N&PAG E=fulltext&AN=18 829799 &D=medl
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaBritishThroacic2008. pdf
http://groups /p2/E BC_Files/Articles_Cited_in_Asthma/AsthmaSimons199 8.pdf
http://groups /ce/EBC_Files/Articles_Cited_in _Asthma_ED/AsthmaSin2002. pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_A sthma/AsthmaSmith 2008.pdf
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaSmith2 009.pdf
http://www.ncb i.nlm.n ih.gov/entrez/query.fcg i?cmd=Retrieve&db=P ubMed&do pt=Citation&lis t_uid s=1 677782 9
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma_ED/AsthmaSoc krider2006. pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaSole199 9PulseOx.pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaSpiegel20 06.pdf
http://ovidsp.ovid.com/ovidweb.cgi? T=JS&NEWS=N&PAGE=fulltext&A N=1 140605 5&D =m ed4
http://groups /p2/E BC_Files/Articles_Cited_in _Asthma/AsthmaTravers2001.PDF
http://groups /p2/E BC_Files/Articles _Cited_in_A sthma/AsthmaVidgren198 1.pdf
Page 34 of 36
154. Walders, N.; Kercsmar, C.; Schluchter, M.; Redline, S.;
Kirchner, H. L.; and Drotar, D.: An interdisciplinary
intervention for undertreated pediatric asthma. Chest,
.
129(2): 292-9, 2006, [2a]
155. Walters, E., Watlers, J Inhaled short-acting beta2-agonists

use in Asthma: Regular versus Needed Treatment
[1a]
.
156. Walters, E. H.; Gibson, P. G.; Lasserson, T. J.; and
Walters, J. A. E.: Long-acting beta2-agonists for chronic
asthma in adults and children where background therapy
contains varied or no inhaled corticosteroid. Cochrane
Database of Systematic Reviews, (1): CD001385, 2007,
[1a]
.
157. Wazeka, A.; Valacer, D. J.; Cooper, M.; Caplan, D. W.;
and DiMaio, M.: Impact of a pediatric asthma clinical
pathway on hospital cost and length of stay. Pediatric
Pulmonology, 32(3): 211-6, 2001, [4a]
.
158. Wilson, S. E.; Leonard, A.; Moomaw, C.; Schneeweiss, S.;
and Eckman, M. H.: Underuse of controller medications
among children with persistent asthma in the Ohio
medicaid population: evolving differences with new
medications. Ambulatory Pediatrics, 5(2): 83-9, 2005,
[4a]
.
159. Wolf, F.; Guevara, J. P.; Grum, C. M.; Clark, N. M.; and
Cates, C. J.: Educational interventions for asthma in
children. Cochrane Database of Systematic Reviews, (4),
2008, [1a]
.
160. Wood, P.; Tumiel-Berhalter, L.; Owen, S.; Taylor, K.; and
Kattan, M.: Implementation of an asthma intervention in
the inner city. Annals of Allergy, Asthma, & Immunology,
97(1 Suppl 1): S20-4, 2006, [4a]
.
161. WorldHealthOrganizationWritingGroup:
Nonpharmaceutical interventions for pandemic influenza,
national and community measures. Emerging Infectious
Diseases [serial on the Internet] www.cdc.gov/eid, 12(1),
2006, [5a]
.
162. Wright, R. S., KA.; jay, GD.; Steele, DW.; : Evaluation of
pre- and posttreatment pulse oximetry in acute childhood
asthma. Academy of Emergency Medicine 4(2): 114-7,
1997, [3b]
.
163. Yilmaz, O.; Sogut, A.; Kose, U.; Sakinci, O.; and Yuksel,
H.: Influence of ambulatory inhaled treatment with
different devices on the duration of acute asthma findings
in children. Journal of Asthma, 46(2): 191-3, 2009, [4a]
.
164. Yoos, H. L.; Kitzman, H.; McMullen, A.; Henderson, C.;
and Sidora, K.: Symptom monitoring in childhood
asthma: a randomized clinical trial comparing peak
expiratory flow rate with symptom monitoring. Annals of
Allergy, Asthma, & Immunology, 88(3): 283-91, 2002,
[2a]
.
165. Zemek, R. L.; Bhogal, S. K.; and Ducharme, F. M.:
Systematic review of randomized controlled trials
examining written action plans in children: what is the
plan? Archives of Pediatrics & Adolescent Medicine,
162(2): 157-63, 2008, [1a]
.
166. Zorc, J. J.; Chew, A.; Allen, J. L.; and Shaw, K.: Beliefs
and barriers to follow-up after an emergency department
asthma visit: a randomized trial. Pediatrics, 124(4):
1135-42, 2009, [2a]
.
http://ovidsp.ovid.com /ovidweb.cg i?T=JS&NEWS =N&PAGE =fullte xt&AN=1647 8844 &D=medl
http://group s/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaWalders2006.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaWalters2002.PDF
Guideline 4
167. Zorc, J. J.; Scarfone, R. J.; Li, Y.; Hong, T.; Harmelin, M.;
Grunstein, L.; Andre, J. B.; and Randomized, t.:
Scheduled follow-up after a pediatric emergency
department visit for asthma: a randomized trial.
Pediatrics, 111(3): 495-502, 2003, [2a]
.
168. Zorc, J. J.; Scarfone, R. J.; Li, Y.; Zorc, J. J.; Scarfone, R.
J.; and Li, Y.: Predictors of primary care follow-up after
a pediatric emergency visit for asthma. Journal of
Asthma, 42(7): 571-6, 2005, [2a]
.
http://groups/ce/E BC_Files/Articles_Cited_in _Asthma_ED/As thmaZorc2003.pdf
http://group s/ce/EBC_ Files/Ar ticles_ Cited_ in_Asthma_ED/AsthmaZorc2005.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaWalters2007.PDF
http://www.ncbi. nlm.n ih.gov/entrez/query.fcgi?cmd=Retr ieve&db=Pu bMed&dop t=Citation&list_uids =11 536450
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthma/AsthmaWazeka200 1.pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaWilson 2005.p df
http://groups /p2/EBC_Files/Articles_Cited_in _Asthma/AsthmaWolf2008.p df
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_ in_Asthm a/AsthmaWood2006.p df
http://www.cdc.gov/ncidod /EID/vol12 no01/05-1371. htm
http://groups /p2/E BC_Files/Articles_Cited_in _ Asthma/AsthmaWright1997 .pdf
http://grou ps/p2 /EBC_ Files /Articles_ Cited_ in_As thma/AsthmaYilmaz2009 .pdf
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_As thma/AsthmaYoos200 2.PDF
http://ovidsp. ovid.com/ovid web.cgi? T=JS &NEW S=N&PAG E=fulltext&D=med l&A N=197864 48
http://gro ups/p 2/E BC_ Files/Articles_ Cited_in_A sthma/AsthmaZemek2008. pdf
http://group s/p2 /EBC_ Files/Ar ticles_ Cited_in_Asthma/AsthmaZorc2009.pdf
Page 35 of 36
Guideline 4
Note: Full tables of evidence grading system available in separate document:

Table of Evidence Levels of Individual Studies by Domain, Study Design, & Quality (abbreviated table below)
Grading a Body of Evidence to Answer a Clinical Question
Judging the Strength of a Recommendation (abbreviated table below)
Table of Evidence Levels (see note above)
Quality level
Definition
1a or 1b
Systematic review, meta-analysis, or meta-synthesis of multiple studies
2a or 2b
Best study design for domain
3a or 3b
Fair study design for domain
4a or 4b
Weak study design for domain
5a or 5b
Other: General review, expert opinion, case report, consensus report, or guideline
5
Local Consensus
a = good quality study; b = lesser quality study
Table of Recommendation Strength (see note above)

Strength
Definition
Strongly recommended
There is consensus that benefits clearly outweigh risks and burdens
(or visa-versa for negative recommendations).
Recommended
There is consensus that benefits are closely balanced with risks and burdens.
No recommendation made
There is lack of consensus to direct development of a recommendation.
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus
process that incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.
1. Grade of the Body of Evidence (see note above)
2. Safety / Harm
3. Health benefit to patient (direct benefit)
4. Burden to patient of adherence to recommendation (cost, hassle, discomfort, pain, motivation, ability to adhere, time)
5. Cost-effectiveness to healthcare system (balance of cost / savings of resources, staff time, and supplies based on published studies or
onsite analysis)
6. Directness (the extent to which the body of evidence directly answers the clinical question [population/problem, intervention,
comparison, outcome])
7. Impact on morbidity/mortality or quality of life
Page 36 of 36

AsthmaFINALGuideline10 14 2010

Diunggah oleh

Informasi Dokumen

Judul Asli

Hak Cipta

Format Tersedia

Bagikan dokumen Ini

Bagikan atau Tanam Dokumen

Opsi Berbagi

Apakah menurut Anda dokumen ini bermanfaat?

Apakah konten ini tidak pantas?

Hak Cipta:

Format Tersedia

AsthmaFINALGuideline10 14 2010

Diunggah oleh

Hak Cipta:

Format Tersedia

Evidence-Based Care Guideline for Management of Acute Exacerbation of Asthma in children aged 0 to 18 years

Health Policy & Clinical Effectiveness Program

Evidence-Based Care Guideline

References in parentheses ( ), Evidence strengths in [ ] (See last page for definitions)

Asthma is a disease of the respiratory tract

Disparities in Quality Care).

Prevalence in children continues to show an increasing

(Akinbami 2009 [4a], Kamble 2009 [4a], MMWR Moorman 2007

and in Puerto Rican and African-American children.

Although this guideline is focused on the management

Emergency Department Management

time of onset of current exacerbation

2. It is recommended that repeat assessments of

3. It is recommended that forced expiratory volume in 1

exacerbations and who currently perform peak flow

(Gupta 2007 [1b], Ralston 2005 [2a], Carl 2003 [2a],

demonstrated a 10% reduction in hospital

levalbuterol to prevent one hospital admission in

Delgado 2003 [2a], Jamalvi 2006 [3a], Benito-Fernandez

spacer is defined as a VHC or

medicine from escaping once you have pressed

Note 3: The inhalation route for SABA

drugs and dosage recommendations).

Table 1: Aerosolized Therapies - Drugs and Dosage Recommendations

6 puffs (range: 4 to 8 puffs)

0.075 mg/kg (minimum dose

For optimal delivery, dilute aerosols to

In mild to moderate exacerbations,

Not necessary as first line therapy in

May mix ipratropium bromide in same

3 mL every 20 minutes for

Ipratropium is not necessary as first

*Children < 12 years of age

Table 2: Corticosteroids - Drugs and Dosage Recommendations

1 mg/kg once daily

Intramuscular (dexamethasone sodium

Abbreviations: ED = emergency department; IV = intravenous; kg = kilogram; max = maximum; mg = milligram

Note 4: If the patient is on routine inhaled

(LocalConsensus [5], SIGN 2008 [5a], NAEPP 2007 [5a]).

Note 5: It is recognized that many children will

an oral aversion to medicine, especially bittertasting corticosteroid preparations. In such cases,

(see Table 3 Adjunctive Therapies - drugs and

Note 2: There is insufficient evidence regarding

improvement in respiratory score and shorter ED

Table 3: Adjunctive Therapies - Drugs and Dosage Recommendations

Child (< 12 years of age)

Systemic (injected) Beta2-Agonists

0.01 mg/kg bolus

0.01 mg/kg bolus

One small study demonstrated more rapid absorption

Timing of Disposition from the Emergency

physical examination and respiratory score

environmental, adherence, financial, psychosocial or

Complementary and Alternative Medicine

the diagnosis of asthma is in question

20. It is recommended that acupuncture not be used for

Mental Health consultation: Patients who have

Social Service Consultation: Indications for

Interpreter Services Consultation: Indication for

Note 3: Patients using theophylline as

24. It is recommended that antibiotics not be used

28. It is recommended that oral albuterol not be used

29. It is recommended that for therapies outlined in this